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ABSTRACT 
Teratogens are chemicals that can cause birth defects in the developing embryo during 
pregnancy. Major structural birth defects affect 2-5% of children, but the etiology of this developmental 
error is often unknown. Exposure to teratogens (chemicals that cause birth defects) during gestation may 
play a causative role in many of these congenital defects. Therefore, it is important to identify teratogenic 
chemicals before pregnant women are exposed to them, but there is no easy, reliable test to determine 
potential teratogenicity of pharmaceutical drugs or industrial chemicals (pesticides, herbicides, solvents, 
etc.). Current developmental and reproductive toxicity (DART) testing uses millions of pregnant animals in 
outdated, inefficient regulatory studies. Embryonic stem cell-based in vitro tests (EST) produce faster, 
clearer results and have the potential to revolutionize DART testing, but they often lack the biologic 
complexity created during embryonic gastrulation and morphogenesis. The embryo is most sensitive to 
teratogenic exposures during the first three to eight weeks of fetal life. During this time, the process of 
morphogenesis shapes nearly all three-dimensional (3-D) organs and tissue structures in the embryo. 
Many of the common birth defects (e.g., neural tube closure defects and cardiac septal defects) are 
caused by disruptions in this vital process. Since morphogenesis drives the formation of fetal structures 
and is often affected by teratogenic drugs, a screen for potential teratogens should incorporate similar 3-
D structural complexity, but this is a common deficit of in vitro teratogenicity tests. Aggregated P19C5 
stem cells spontaneously form “embryoid bodies” (EBs) and recapitulate the germ layer differentiation 
and structural remodeling that occur during embryonic gastrulation and morphogenesis. Exposure to 
teratogens disrupts EB morphology, making P19C5 morphogenesis a sensitive indicator of 
developmental toxicity. In this research project, I validated the P19C5 system as a morphology-based 
teratogen-screening assay and demonstrate that the P19C5 assay can be used to investigate teratogenic 
mechanisms that cause structural defects. We expect that this test will allow us to accurately identify 
chemicals that may cause fetal malformations and help us understand the mechanisms of teratogenic 
chemicals in order to reduce the number of children born with preventable birth defects. 
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CHAPTER 1. BACKGROUND 
1.1 - Birth defects and teratogens 
Major structural birth defects affect 3% of newborns, but the etiology of the congenital defect is 
unknown in nearly 50% of these cases (Rynn et al., 2008). Environmental exposures, including exposure 
to teratogenic chemicals may play a causative role in many of the unknown cases (Sadler, 2012). Birth 
defects are the result of abnormal development due to either genetic mutations or external factors that 
disrupt normal developmental processes in specific tissues or structures without causing overt embryonic 
or maternal death. These external factors are called teratogens, a broad term that includes drugs and 
chemicals, radiation, viral or bacterial infections, hyperthermia, and maternal metabolic conditions. A 
culturally relevant example of a viral teratogen is the Zika virus, which crosses the placenta and 
preferentially infects and kills the neural progenitor cells of the developing embryos leading to 
microcephaly in affected infants (Russo et al., 2017). Developmental toxicants (teratogenic chemicals) 
are by far the largest class of teratogens, and the number of chemical teratogens that we are exposed to 
on a daily basis continually increases as we synthesize and process new compounds and materials. Over 
the course of her pregnancy, a woman may encounter many developmental toxicants in the form of 
medications, supplements, occupational exposures, contaminated food or water, secondhand smoke, 
alcohol and illicit drugs (Jacqz-Aigrain and Koren, 2005).  
The concept of teratogens was not widely accepted until the early 1960’s. Previously, the 
scientific and medical community assumed that most birth defects were caused by genetic mutations and 
that the embryo was fully protected from any harmful environmental factors by the placenta. We now 
know, of course, that both natural and man-made teratogens have been causing birth defects for a very 
long time. For example, cyclopamine and jervine, two naturally occurring chemicals produced by the 
California corn lily (Veratrum californicum), cause holoprosencephaly or cyclopia in offspring of animals 
that graze on it. These two teratogens inhibit cholesterol synthesis and the Sonic hedgehog (Shh) 
signaling pathway. Since Shh is a crucial regulator of facial morphogenesis, its inhibition leads to cyclopia 
(Gilbert, 2010). A similar phenotype can be created in humans or animals with genetic mutations in the 
Shh pathway, demonstrating that very similar syndromes of birth defects can be caused by genetic or 
teratogenic factors that both disrupt the same developmental process.  
There are also some naturally occurring compounds that are necessary for normal development, 
but that become teratogenic if the embryo is exposed to excessively high or low levels. The best example 
of this is retinoic acid (RA), the active form of vitamin A. Like Shh, the RA signaling pathway is another of 
the major signaling pathways that regulate normal embryonic development (Niederreither et al., 1997; 
Tonk et al., 2015; Sakai et al., 2001; Rhinn and Dolle, 2012). In its active form, RA regulates the spatial 
and temporal patterns of homeobox (Hox) gene expression as well as interacting with the other major 
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signaling pathways (i.e., the Wnt, Fgf, Notch, Nodal and Bmp pathways) to establish the anterior-posterior 
axis and the embryonic body plan early in development. Because RA is responsible for patterning and 
development of the pharyngeal arch derivatives and the caudal body, abnormal levels of RA (or 
chemicals that disrupt RA signaling) are highly likely to cause characteristic defects that include small or 
absent ears and jaws, cleft palate, aortic arch abnormalities and neural tube defects (NTD) (Tonk et al., 
2015). This demonstrates that some teratogens cause predictable birth defects based on their molecular 
mechanism and the developmental process that they disrupt. 
Endocrine disruptors are another class of teratogenic compounds that are increasingly ubiquitous 
in our society. The endocrine system is composed of glands that secrete endocrine, paracrine and 
autocrine hormones as well as the receptors that respond to these secreted hormones. An endocrine 
disruptor is defined as “an exogenous agent that interferes with the production, release, transport, 
metabolism, binding, action or elimination of natural hormones in the body responsible for the 
maintenance of homeostasis and the regulation of developmental processes” (Kavlock et al., 2012). The 
development of embryonic genitalia is particularly sensitive to disruption by variability in the levels of the 
steroid sex hormones (e.g., androgens and estrogens). Therefore, chemicals that interfere with normal 
androgen or estrogen signaling have potent effects in embryos, even at levels that are innocuous in adult 
humans. A notorious example is bisphenol A (BPA), which is used as a stabilizer in polycarbonate 
plastics and is produced at a rate of 2 billion pounds per year in the US. Unfortunately, BPA leeches out 
of plastics into water or food at levels that are high enough to alter the reproductive organs of developing 
frogs, mice, primates and humans. In humans, exposure to BPA in utero causes a prostate enlargement 
and a decline in sperm count in men and increases the rate of mammary tumors in women. Other 
endocrine disruptors include dichlorodiphenyltrichloroethane (DDT; a now-banned pesticide), phthalates, 
acrylamide, nonylphenol and genistein, to name a few. It is suspected that estrogenic endocrine 
disruptors are responsible for the increasing rates of “testicular dysgenesis syndrome” (TDS) in human 
males worldwide. Male infants born with TDS have poorly formed external genitalia, low sperm counts 
and a higher risk of testicular cancer (Gilbert, 2010).  
1.2 - Identification of teratogens: Human epidemiology 
Clearly it is important to identify potential teratogens and prevent maternal exposures to 
teratogenic chemicals. Unfortunately, it is difficult to study teratogens in mammalian pregnancies and the 
current methods used to screen for teratogens—retrospective epidemiologic studies on humans and in 
vivo testing using animal models—are ineffective and inefficient, respectively.  
Although retrospective epidemiologic studies on birth defects in human pregnancies have 
identified a few of the earliest and most notorious teratogens, they are an ineffective way of preventing 
the burden of teratogen-induced birth defects in human pregnancies. To achieve a sample size sufficient 
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to identify a drug or medication as a teratogen in an epidemiologic study, the teratogenic agent in 
question must have already caused thousands of birth defects that could easily have been prevented. For 
instance, thalidomide was widely prescribed to pregnant women in the 1960’s to treat morning sickness 
and was only identified as a teratogen once the medical field noted a high incidence of babies born 
without arms or legs, a condition called phocomelia (Gilbert, 2010). 
Human gestation is divided into two stages: the embryonic period in the first eight weeks and the 
fetal period spanning the remainder of gestation. Most teratogen-induced birth defects occur between 
three and eight weeks after conception. In the first three weeks of the embryonic period, teratogens are 
unlikely to cause congenital malformations because the embryo has not undergone gastrulation and the 
formation of the three germ layers. Before embryonic cells become committed to a single cell lineage, 
they are pluripotent, meaning they can become any of the cell types in body. At this stage, a teratogenic 
insult is likely to either kill the entire embryo or damage only a few pluripotent cells without causing lasting 
effects in the embryo. At approximately three weeks post-conception, the pluripotent cells of the epiblast 
become either embryonic ectoderm (the source of neural crest cells, central nervous system [CNS], and 
surface ectoderm [skin/hair/teeth, etc.]), endoderm (the future epithelial and secretory lining of the lungs 
and gastrointestinal (GI) tract) or mesoderm (the source of musculoskeletal, cardiovascular and other 
visceral tissue) through the process, called gastrulation. After gastrulation is the period of organogenesis, 
during which the pluripotent embryonic cells become committed to specific progenitor cell lineages, each 
equipped to eventually differentiate into a single organ or tissue type. A teratogenic disruption to a 
specific progenitor cell population inhibits either the migration, differentiation or survival and proliferation 
of the cells and has lasting effects that are amplified as the organ or structure continues to develop.  
During the embryonic stage, organs and body structures develop at different times and have 
correspondingly different periods of susceptibility to teratogenic disruption. Thalidomide causes a specific 
sequence of abnormalities that depend on the timing of the embryo’s exposure (Fig. 1.1A). Although it is 
only teratogenic between 20 to 36 days of gestation, a single dose of thalidomide can cause a baby to be 
born with all four limbs absent or severely shortened. If the exposure occurs in day 20 to day 24, only the 
ears are abnormal. Exposure between day 24 to day 32 results in phocomelia of the arms and legs, 
whereas exposure on day 32 to 36 only causes abnormalities in the formation of the thumbs. This 
demonstrates an important point, teratogenic effects are determined by the timing, dose and duration of 
the teratogenic exposure. Despite the dramatic malformations that thalidomide causes, nearly 10,000 
children were born with thalidomide syndrome before the connection between thalidomide and 
phocomelia was made and it was withdrawn from the market (Gilbert, 2010). Not all teratogenic 
syndromes are distinctive enough to attract attention and implicate a single teratogenic agent, and this is 
a weakness of identifying teratogenic chemicals through epidemiologic studies.  
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Alcohol is a more subtle developmental toxicant than thalidomide, but it is undeniably one of the 
most devastating teratogens due to its high prevalence of use and the severity of the debilitation it 
causes. Fetal alcohol syndrome (FAS) was described in children born to alcoholic mothers in 1968. FAS 
is characterized by stunted growth and distinctive facial defects that include a small head, thin upper lip, 
smooth philtrum and small palpebral fissures of the eyes. Children with FAS often also have structural 
defects in their hearts, kidneys, or skeleton in addition to the characteristic facial features. The defective 
neuronal development that contributes to the small head size in affected children also results in FAS 
being the most common congenital mental retardation syndrome, affecting in 1 in 650 children born in the 
United States. Fetal alcohol spectrum disorder (FASD) is the diagnosis used for children affected by in 
utero alcohol exposure that do not meet all the criteria for an FAS diagnosis, and FASD is at least three 
times as prevalent as FAS. Unlike thalidomide, there is wide variability in the type and the severity of 
alcohol-induced birth defects. Individuals vary widely in their ability to metabolize alcohol and that fact—
along with substantial variation in the timing and dosage of fetal exposure—means that FAS and FASD 
manifest as a broad spectrum of structural defects. Additionally, alcohol appears to cause developmental 
toxicity via multiple molecular mechanisms, including the disruption of neural crest cell migration and 
differentiation, interference with cytoskeletal rearrangement, inhibition of normal Shh signaling, impaired 
cell-cell adhesion and toxicity in the cell populations that form the forebrain, cranial nerves and face. 
The variability seen in FAS and FASD is a perfect example of the phenotypic variability that 
makes it so difficult to use epidemiologic reports to study teratogens in human pregnancies. Also, since 
the period of highest susceptibility to teratogens very early, a mother may not even be aware that she is 
pregnant and thus she is unlikely to monitor environmental exposures (Sadler, 2012). Additionally, the 
noise created by variability in maternal lifestyle, metabolism and individual gene-environment interactions 
often confounds the effects of heterogeneous environmental exposures. Thus, it is exceptionally difficult 
to sift through all factors affecting a pregnancy and pinpoint a single causative agent. Epidemiologic 
studies will continue to be useful, particularly with the conversion to electronic medical records and 
increasingly comprehensive birth defect reporting systems. However, additional prophylactic screening 
methods are necessary to prevent unnecessary birth defects in human pregnancies.  
1.3 - Identification of teratogens: Animal studies 
As a result of the thalidomide crisis, the FDA instituted regulations requiring that new medications 
undergo testing to screen for teratogenic potential. The regulation and study of teratogens has been 
guided by six principles proposed by James G. Wilson in 1959:  
“Wilson’s Principles: 
(A) Susceptibility to developmental toxicity depends on the genotype of the conceptus and 
the way this interacts with adverse environmental factors.  
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(B) Susceptibility to developmental toxicity varies with the developmental stage at the time 
of exposure to an adverse influence.  
(C) Developmental toxins act in specific ways (mechanisms) on developing cells and tissues 
to initiate sequences of abnormal developmental events (pathogenesis).  
(D) The access of adverse influences to developing tissues depends on the nature of the 
influence (agent).  
(E) The four manifestations of deviant development are death, malformation, growth 
retardation, and functional deficit… 
(F) Manifestations of deviant development increase in frequency and degree as dosage 
increases [dose-responsiveness], from the no effect to the totally lethal level.” (Faqi et 
al., 2012) 
The first of Wilson’s principles has two parts: 1) certain species respond differently to particular 
teratogens and 2) individuals of the same species show variation in the frequency and intensity of 
teratogen-induced abnormalities. As a result, regulatory developmental and reproductive toxicology 
(DART) testing is done using at least two species of model animals, one rodent and one non-rodent 
mammal. Additionally, multiple replicates of each experiment are performed to address individual 
variability within a single species. The second principle highlights the fact that the period of highest 
teratogenic susceptibility is early in the first trimester, but that different organs have different windows of 
susceptibility, as seen in the case of thalidomide. In concordance with the second principle, experiments 
are conducted to assess the effects of chemical exposures at different stages in the pregnancy (i.e., 
parental exposure pre-conception, and then treatment of pregnant females either early, mid-, or late in 
gestation). To identify the dose-response curve described in the sixth principle, chemical exposures are 
administered in a range of concentrations that starts at the “no observable adverse effect level” (NOAEL) 
and “lowest observed adverse effect level” (LOAEL) to the concentrations at which the chemical begins to 
cause maternal toxicity. Finally, the endpoints of the regulatory experiments assess whether in utero 
exposure to the chemical causes: 1) fetal mortality, 2) congenital malformations, 3) alterations to growth, 
or 4) functional toxicity after birth (principle four).  
The testing methods for developmental and reproductive toxicity (DART) have remained 
essentially unchanged since they were first instituted in 1966. Since early embryonic development in 
mammals is very similar, animal models are the gold standard method to assess potential developmental 
toxicity of chemicals within the context of a placental pregnancy. The embryologic process of gastrulation 
and germ layer formation is orchestrated by a few major developmental signaling pathways—such as 
Wnt, Bmp, Fgf and retinoic acid—that coordinate the developmental fate of each fetal cell, establishing 
body axes and directing cellular migration and interactions (Tam and Loebel, 2007; Tam et al., 2006). 
These crucial signaling pathways are highly conserved across species, often allowing teratogenic effects 
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to manifest similarly in different species of animal models. Additionally, early mammalian embryos share 
nearly identical homologous structures (i.e., limbs, heart) and similar body patterning. The specialized 
adaptations that distinguish adult forms of different species do not appear until structural remodeling 
occurs later in development. Thus, teratogenic impacts in the first trimester of human pregnancies are 
often reflected in similar malformations across other non-human species.  
However, there are also a number of drawbacks to relying so heavily on in vivo teratogenicity 
assessments. First, there is some variability in the impact of teratogenic chemicals between species. 
Thalidomide was not initially identified as a teratogen because mice and rats are non-responsive to its 
teratogenic effects. Although rabbits show slight malformations after in utero exposure, the only reliable in 
vivo DART model for thalidomide is non-human primates (NHP). Additionally, all in vivo models require 
specialized facilities and trained handlers. The high cost of in vivo DART testing translates to high costs 
for drug development and delays the approval process of new therapeutics. It also gives a competitive 
advantage to the Big Pharma companies because it is prohibitively expensive for smaller companies to 
bring drugs to market. Third, the extensive experiments required to perform a thorough DART evaluation 
for a single chemical combined with the large number of compounds that need to be evaluated mean that 
DART testing has some of the highest rates of live-animal usage in research, raising ethical and animal 
welfare issues. Finally, it is very difficult to study the molecular mechanisms of teratogenic effects using in 
vivo models—a concept which is addressed in Wilson’s third principle, but that is notably absent from 
regulatory testing of medications and industrial chemicals. Without understanding how a teratogen 
causes malformations, it is difficult to confidently translate positive (teratogenic) results from animal 
studies into an accurate prediction of teratogenic risk in humans. Therefore, the need for mechanistic 
evaluations of teratogenic pathogenesis is at the forefront of developmental toxicity research, but the 
tools to investigate teratogenic mechanisms are still emerging. Altogether, these issues highlight the need 
for additional methods in developmental toxicity testing that will refine and complement in vivo 
teratogenicity tests.  
1.4 - Identification of teratogens: In vitro models 
In vitro testing methods have the potential to augment in vivo screens in a way that will increase 
efficiency and accuracy of DART testing as well as reduce the volume and cost of animal-based tests. In 
vitro methods offer a standardized testing environment that is a simplified version of normal in vivo 
processes. These methods provide a system that is robust to experimental manipulations and is easily 
accessed for data collection or visualization of results. Another benefit of alternative model systems is the 
ability to monitor the exact treatment concentrations, whereas in in vivo testing, animals are dosed by 
body weight and the actual fetal exposure level is unclear. Similarly, in vitro models provide a platform for 
experiments that are very difficult or impossible in live animals, including genetic manipulations like 
transfection, reporter assays, gene knockouts, etc. Additionally, in vitro tests may be used in conjunction 
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with human hepatic enzymes to mimic human metabolism—identifying seemingly harmless 
“proteratogens” that require enzymatic activation before they cause effects—bypassing the issue of non-
human metabolism and individual variability in a way that is nearly impossible using animal-based testing. 
All of these advantages mean that there has been substantial interest in the development of in vitro 
teratogen screening assays able to easily and accurately identify teratogens. In fact, this was a central 
focus of the 2017 Teratology Society conference, where leading developmental toxicologists evaluated 
the current regulatory protocols for developmental toxicity testing and recommended modifications and 
future directions of the field (Scialli et al., 2018). In the resulting publication, Scialli et al. (2018) write that 
in vitro and in silico models are the future of teratogenicity testing because they are compatible, “with 
hypothesis-driven testing where we take what we know about a compound or close analog and answer 
specific questions using targeted experimental techniques rather than a one-protocol-fits-all approach” 
(Scialli et al., 2018). In vitro tests offer the advantage of clearer analytic endpoints and the flexibility to 
perform mechanistic evaluations to assess how individual chemicals cause teratogenic effects.  
Embryonic stem cell (ESC)-based tests have been explored as alternatives to in vivo teratogen 
screening assays for developmental toxicology. ESCs are derived from the inner cell mass of 
preimplantation embryos. These stem cells are pluripotent, self-renewing and retain the ability to respond 
to the major signaling pathways that regulate embryonic development. Pluripotency is the capacity to 
differentiate into any cell type of the embryonic body, including derivatives of all three germ layers 
(endoderm, mesoderm and ectoderm). ESCs retain the pluripotency of the ICM in vitro and can be 
directed to differentiate into several cell types by altering culture conditions or adding signaling molecules 
such as growth factors, hormones, chemicals or proteins (Yu and Thomson, 2008). The goal of in vitro 
testing is to provide a detailed and realistic picture that will clarify our understanding of the unclear or 
unknown processes occurring in vivo, and eventually will allow better prediction of teratogenic drug 
effects in human pregnancies. Thus far, only the cardiomyocyte embryonic stem cell test (ESTc) 
(Genschow et al., 2002) has been extensively explored by other researchers as a suitable in vitro 
alternative for teratogenicity screening (Estevan et al., 2009). The principle behind the ESTc resulted from 
Wobus et al. observing that when embryonic stem cells (ESCs) are aggregated in hanging drop culture to 
form embryoid bodies (EBs), the ESCs differentiated into progenitor cells of all three germ layers (Wobus 
et al., 1988). Treatment with retinoic acid, a well known teratogen, altered the time course and 
developmental fate of the differentiating ESCs (Estevan et al., 2009). Building on the changes seen in 
temporal and lineage specification after teratogenic treatment, ESTc uses ESCs that spontaneously 
differentiate into cardiomyocytes and evaluates a compound’s ability to inhibit both differentiation and 
proliferation (or viability) of the ESCs (Spielmann and Liebsch, 2001). After 10 days, ESC shape and 
contractility are semi-quantitatively measured to determine the extent of teratogenic effects on 
differentiation. However, the original ESTc is time-consuming, technically challenging, and uses only a 
single tissue type (cardiomyocytes) for differentiation studies.  
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Numerous publications have attempted to improve upon the original ESTc design by 
incorporating additional analytic endpoints, differentiation pathways or quantitative models. However, the 
variations of EST continue to adhere to the original format, which assesses differentiation and 
proliferation of a single embryonic cell line. Modifications to EST (additional cell types, molecular 
endpoints, reporter-based systems, etc.) increased the sensitivity, but also increased the EST’s time 
frame and complexity, making it laborious as a screening test (Estevan et al., 2009). Despite the many 
variations and modifications, a test based solely on cytotoxicity and cardiomyocyte differentiation may not 
be comprehensive enough to serve as a broad screening assay for teratogens. According to Trosko and 
Chang (2010), the “ultimate potential for in vitro testing” will be realized using a “3-D in vitro micro-
environment;” however, the typical EST lacks 3-D structural complexity and other microenvironment 
components encountered in vivo (Trosko and Chang, 2010). This issue was also discussed by Scialli et 
al. (2018) as well, as they wrote, “Experimental models that reduce a complex biological system to 
simpler assays have the benefit of facilitating quantitative evaluation of cellular and molecular responses 
to chemical perturbation but at the drawback of eliminating the cellular interactions and spatial dynamics 
that make an embryo complex in the first place. When modeling developmental processes and the toxicity 
that disrupts them, we need to rebuild this complexity.” (Scialli et al., 2018) Although in vitro tests have 
the potential to greatly reduce the animal-usage burden imposed by teratogenicity testing, only an in vitro 
system that reflects both teratogenic susceptibility and the complexity of early embryonic development 
can reasonably reduce animal usage in the field of developmental toxicity. 
1.5 - A new tool for teratogen research: The P19C5 in vitro 
gastrulation model 
The embryo is most sensitive to teratogenic exposures during the period of gastrulation and 
organogenesis when crucial developmental regulatory pathways—such as Wnt, BMP, Fgf and retinoic 
acid—coordinate the developmental fate of each fetal cell, establishing body axes and directing cellular 
migration and interactions (Tam and Loebel, 2007; Tam et al., 2006). These complex events all contribute 
to embryonic morphogenesis, the process that creates three-dimensional structures and tissues in the 
embryo. Many of the most common birth defects (neural tube closure defects, cardiac septal defects, cleft 
palate, etc.) are the result of genetic or environmental disruptions in morphogenetic process (Herion et 
al., 2014; Wilde et al., 2014). To model in vivo effects, a teratogen screening assay should evaluate 
adverse impacts on differentiation, as well as embryonic body patterning and morphogenesis. 
Unfortunately, this type of structural complexity is difficult to replicate in vitro and is a common deficit in 
stem cell-based teratogenicity tests (Lee et al., 2012) 
To address the challenges faced by former in vitro tests, we propose a novel morphogenesis-
based stem cell assay as a screen for developmental toxicants. Similarly to the EBs formed by Wobus in 
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1988, EBs of aggregated P19C5 stem cells undergo a process of gastrulation and germ layer formation 
(Marikawa et al., 2009; Wobus et al., 1988). Unlike the original ESC EBs or the EST cardiomyocytes, the 
P19C5 aggregates are able to spontaneously establish and elongate along a cranial-caudal ‘body’ axis, 
recreating the process of embryonic morphogenesis in vitro (Fig. 2.1A,C). P19C5 EBs appear to recreate 
the embryonic process of gastrulation and elongation morphogenesis in vitro. During gastrulation, the 
mass of embryonic cells in the epiblast forms three separate germ layers from which all the structures in 
the body are derived (Tam and Loebel, 2007; Pfister et al., 2007). Gastrulation begins with the formation 
of the primitive streak, which elongates towards the caudal end of the embryo. The elongation of the 
primitive streak is driven by epiblast cells that undergo an epithelial-mesenchymal transition (EMT) and 
migrate through the primitive streak where they become endoderm and mesoderm.  
The P19C5 EBs show temporal and spatial gene expression patterns that mirror the gene 
expression of gastrulating embryos. Many of the key developmental regulator genes known to be 
expressed in the primitive streak and posterior mesoderm of mouse embryos at E6.5 to E8.5 increase 
over the course of four days in hanging drop culture, including: Brachyury, Sp5, Fgf8, Snai1, Lhx1, Tbx6, 
Hoxb1, Cdx2 and Wnt family members (Wnt3, Wnt3a, Wnt5a, and Wnt8a). As would be expected in a 
differentiating cell mass, pluripotency genes (such as Pou5f1, Foxd3 and Eras1) decrease after P19C5 
EB aggregation (see Pou5f1 in Fig. 4.4), and the temporal expression patterns follow the sequences seen 
in gastrulating embryos. Namely, Brachyury expression peaks at Day 1 (marking the primitive streak) 
followed by Day 2 peaks in the expression levels of mesoderm-associated markers, such as Wnt3a 
(EMT) and Tbx6 (paraxial mesoderm), whereas the expression level of Meox1 (somitogenesis) does not 
peak until Day 3 (Marikawa et al., 2009; Lau and Marikawa, 2014; Li and Marikawa, 2015). Additionally, 
whole-mount in situ analysis (WMISH) shows regionalized gene expression in P19C5 EBs that indicates 
the presences of a cranial-caudal body axis. The consistent, synchronous morphologic change seen in 
P19C5 EBs as they morph from ovoids on Day 3 to distinctly elongated forms on Day 4 is characteristic of 
convergent extension, a process uniquely seen in axial and paraxial mesoderm during elongation 
morphogenesis of the embryo along the cranial-caudal axis (Fig. 2.1A, C).  
After migratory epiblast cells enter the primitive streak, local embryonic characteristics such as 
body patterning, cell-cell interactions and 3D structural elements direct the pluripotent cells towards 
specific development pathways, identifying them as the precursors for a specific tissues or organs 
(Loebel et al., 2003; Li et al., 2003; Kruegel and Miosge, 2010). This dynamic remodeling of tissue 
identity and architecture is called morphogenesis. Morphogenesis literally means, “the creation of form,” 
thus, embryonic morphogenesis is aptly named, because it is the process that shapes all the major 
structural features of the embryonic face, limbs, vital organs, neural tube and body axes during the first 
three to eight weeks of gestation (Tam et al., 2006; Sadler, 2012). Most of the common birth defects are 
caused by slight abnormalities in the process of embryonic morphogenesis, and many teratogenic 
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malformations are the result of exogenous insults to the morphogenetic process (Herion et al., 2014). 
Experiments using pharmacologic inhibitors of major developmental signaling pathways showed 
alterations in both P19C5 EB elongation morphogenesis and gene expression profiles like what would be 
expected if those drugs were used on a developing embryo in vivo (Li and Marikawa, 2015). This implies 
that EB morphogenesis is a sensitive indicator of teratogenic effects and may aid the generation of an in 
vitro alternative to animal-based teratogenicity screens. Additionally, because embryonic morphogenesis 
depends on the collective functionality of molecular, cellular and tissue-level mechanisms, the parallel 
process of EB morphogenesis will enhance the analytic power of toxicological models, which attempts to 
assess dynamic teratogenic mechanisms rather than static analytic endpoints (Gocht et al., 2015; Daston 
et al., 2015). To the best of our knowledge, this kind of morphogenesis-based in vitro assay has never 
been submitted for validation as a developmental toxicity screening technique.  
The P19C5 elongation morphogenesis model has the potential to advance the search for an 
accurate in vitro teratogenicity test, because it encompasses the complexity of gastrulation and germ 
layer formation in an exceptionally simple, cost-effective hanging drop culture system over four days. The 
successful elongation of the EBs demonstrates that all the major developmental signaling pathways are 
intact, allowing quantification of drug impacts using simple image analysis software, ImageJ, which is 
freely available from NIH. Additionally, the ability to comprehensively investigate the molecular 
mechanisms of teratogenic effects will allow directed drug development to avoid unintended side effects 
or off-target actions of new pharmaceuticals. Finally, the simplicity and robustness of the P19C5 system 
allows for additional modifications such as gene transfection, or human metabolic enzyme additions to 
more closely mimic the impacts of teratogens on human embryonic development.  
The following chapters will describe the work I have done during my Ph.D. project to validate the 
P19C5 model against two separate panels of chemicals and to use the P19C5 model to understand the 
previously unknown teratogenic mechanism of a commonly used antidepressant. The first validation 
study assessed whether the P19C5 model was capable of a binary classification, i.e., teratogenic or non-
teratogenic, of 20 drugs known to be either safe (FDA pregnancy Category A or B) or teratogenic (FDA 
pregnancy Category X) at concentrations of 0.1 µM, 1 µM, 10 µM, and 100 µM. In the Category X 
validation study, the P19C5 model correctly identified 81% of Category X drugs as potential teratogens 
using the morphometric parameters of EB area and EDI (elongation distortion index). The Category X 
validation study was followed by a validation study that tested the P19C5 model against chemicals in the 
Daston Validation Panel. This study adjusted the concentrations of chemical exposure to match the levels 
that previously demonstrated teratogenic effects in rodents in vivo and, therefore, assessed whether the 
P19C5 model was capable of responding to teratogens at concentrations comparable to the levels an 
embryo might encounter during pregnancy. The P19C5 model was able to correctly classify chemicals as 
teratogenic or safe (within a four-fold concentration margin) with an accuracy of 82%. The third aspect of 
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my research applied the P19C5 model to a mechanistic investigation of the potential teratogenicity of 
fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant. In this portion of my research, I 
found that fluoxetine appears to inhibit canonical Wnt signaling, an important signaling pathway in 
development. Finally, in Chapter 5, I will further discuss the implications and applicability of my studies 
and future research directions. 
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Figure 1.1. Susceptibility to teratogenic disruption is highest during the embryonic period of development 
and the outcome of a teratogenic exposure depends on the developmental stage at the time of exposure 
and the nature of the teratogen. (A) Organ systems form at different times and have correspondingly 
different periods of teratogenic susceptibility. Teratogenic exposure during a susceptible period can cause 
major structural birth defects (red) or functional defects and minor anomalies (yellow). (B) Exposure to 
even a single dose of thalidomide causes a syndrome of dramatic congenital malformations. The timing of 
thalidomide exposure determines the type of malformations seen in affected infants. (C) Thalidomide 
syndrome was identified in the 1960’s due to the unusually high number of exposed infants born with the 
rare condition, phocomelia, which is characterized by an absence of the long bones of the arms and legs. 
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CHAPTER 2. VALIDATION OF THE P19C5 MORPHOGENESIS MODEL – 
CATEGORY X DRUGS 
2.1 - Introduction 
Exposure to certain chemical agents during pregnancy may disturb the normal course of embryo 
development. The nature of developmental toxicity varies depending on chemical properties of agents, 
dosage, and timing of exposure. For example, chemicals that interfere with essential metabolic processes 
may cause death of early embryonic cells, leading to embryo loss at very early stages of gestation, 
perhaps even before the pregnancy is detected. Other developmental toxicants may delay embryonic cell 
cycles, which can result in growth retardation or spontaneous abortion. Cell differentiation may be 
impaired by chemicals in a tissue type-specific manner, leading to agensis or hypoplasia of the affected 
organs. Furthermore, developmental toxicants may interfere with cellular behaviors, collectively known as 
morphogenesis, such as cell migration, adhesion, or shape changes. Morphogenetic disturbance leads to 
structural anomalies, as found in various common birth defects, such as neural tube closure defects, 
heart septal defects, hypospadias, and cleft lip and palate (Parker et al., 2010; Sadler, 2012). Because 
the process of embryogenesis is spatially and temporally complex, integrating cellular proliferation, 
differentiation, and morphogenesis, identification of developmental toxicants is a highly challenging task 
and requires multiple investigative approaches. 
Many of the chemicals that are considered developmentally toxic or teratogenic to humans were 
identified through human epidemiologic studies (Friedman, 2009; Chaabane and Bérard, 2013). However, 
the identification of developmental toxicants using such retrospective methods can be achieved only after 
a significant number of tragic incidences have already happened. In order to predict potential 
developmental toxicity of new pharmaceutical agents before they are introduced to the market, chemical 
regulatory agencies, such as FDA, mandate a series of developmental toxicity tests using model animals 
(Daston, 2011). However, these animal-based tests also have disadvantages. Metabolic differences 
between species influence pharmacokinetics of drugs, causing large inter-species variations in the 
teratogenic dose, possibly resulting in incorrect classifications of potential developmental toxicants (Bailey 
et al., 2005; Hartung, 2011). Furthermore, regulatory reproductive and developmental toxicology testing is 
the largest consumer of experimental animals, posing tremendous financial and ethical burdens to the 
society and the pharmaceutical industry (Hartung and Rovida, 2009). The establishment of effective and 
economical alternatives to animal-based developmental toxicity tests may ameliorate the impact of 
metabolic variation between species and reduce the number of animals used in toxicology studies. 
In vitro toxicity tests using embryonic stem cells, collectively known as embryonic stem cell tests 
(EST), have been explored as non-animal alternatives in developmental toxicology. Embryonic stem (ES) 
cell lines derived from the epiblast of pre-implantation stage embryos are capable of differentiating into 
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various cell types in vitro (Yu and Thomson, 2008). In EST, potential developmental toxicity of chemicals 
is assessed based on their ability to inhibit in vitro differentiation of ES cells in relation to their cytotoxic 
impact on ES cell and somatic cell lines, such as NIH/3T3 fibroblast. The original EST, or ESTc, 
measures inhibitory effects of chemicals on cardiomyocyte differentiation (Spielmann et al., 1997). ESTc 
performed well in the initial validation study (Genschow et al., 2002), but it yielded a poor result in a 
follow-up study (Marx-Stoelting et al. 2009; Riebeling et al., 2012). Subsequently, numerous attempts 
have been made to improve upon the original EST by utilizing additional differentiation pathways (e.g., 
neurons and osteoblasts) and analytic methods (e.g., expression of tissue-specific molecular markers, 
transcriptional profiling, and toxicogenomic analysis) (zur Nieden et al., 2001; Buesen et al., 2004, 2009; 
Seiler et al., 2004; Suzuki et al., 2011; Seiler and Spielmann, 2011; van Dartel and Piersma, 2011; de 
Jong et al., 2012; Hayess et al., 2013; Panzica-Kelly et al. 2013; Gao et al., 2014; Li et al., 2015). 
However, in vivo embryogenesis involves coordinated differentiation and morphogenesis of hundreds of 
different cell types to construct organized body architectures. Each in vitro system represents only a 
limited aspect of this highly complex process. Therefore, rather than relying on a single system, it would 
be more realistic and productive to employ multiple in vitro models, each of which recapitulates unique 
aspects of embryogenesis, to detect a wide range of developmental toxicants. Because current versions 
of EST are based mainly on cell differentiation, additional models incorporating morphogenesis aspects 
may enhance the versatility of in vitro assays and allow the identification of a more diverse array of 
developmental toxicants. 
Previously, we demonstrated that aggregates, or embryoid bodies (EBs), of P19 mouse 
embryonal carcinoma stem cells exhibit axial elongation morphogenesis in vitro (Marikawa et al. 2009; 
Lau and Marikawa, 2014). The P19 cell line was originally isolated from a mouse teratocarcinoma, which 
was created by transplanting a normal post-implantation embryo into testes (McBurney and Rogers, 
1982). P19 cells are developmentally pluripotent, meaning that they are capable of differentiating into 
derivatives of three germ layers. P19 cells have been used by many researchers as an effective in vitro 
model to investigate the molecular mechanisms of embryonic cell differentiation (McBurney, 1993; Bain et 
al., 1994, Skerjanc, 1999; van der Heyden and Defize, 2003; Hohjoh, 2013; Voronova et al., 2013). In 
vitro morphogenesis of the P19 subclonal line, P19C5, recapitulates the key aspects of gastrulation 
driving germ layer formation and convergent extension along the cranial-caudal body axis in early 
embryos (Marikawa et al., 2009; Lau and Marikawa, 2014). Developmental regulator genes, particularly 
those involved in gastrulation, mesendoderm formation, axial patterning, caudal extension, and 
somitogenesis, are expressed during P19C5 EB morphogenesis in a temporally and spatially specific 
manner comparable to their in vivo expression patterns. Furthermore, P19C5 EB elongation is dependent 
on key developmental signals involved in cell differentiation and embryo patterning, including Wnt 
signaling pathways (Marikawa et al., 2009), suggesting that the EB morphogenesis is controlled by the 
same molecular machineries that regulate early development in normal embryos. P19C5 EBs display 
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consistent size growth and elongation within four days of culture in hanging drops, which are easily 
accessible for experimental manipulations. Thus, the P19C5 EB model may be used to effectively 
investigate the impact of chemical agents on embryonic growth, differentiation and morphogenesis. 
In the present study, we explored P19C5 EBs as an in vitro tool to assess the impacts of 20 
therapeutic drugs (Table 2.1). Sixteen of the treatment drugs are contraindicated during pregnancy due to 
their developmental and reproductive risks (FDA Pregnancy Risk Category X), whereas four are 
considered safe to be used during pregnancy (FDA Pregnancy Risk Category A). The drugs selected for 
this exploratory study encompass a wide spectrum of therapeutic targets and chemical properties. The 
panel of treatment drugs includes agents that affect: 1) lipid metabolism (orlistat [lipase inhibitor] and 
lovastatin [HMG-CoA reductase inhibitor]); 2) steroidal sex hormone signaling (mifepristone [anti-
progesterone], bicalutamide [anti-androgen], diethylstilbestrol [synthetic estrogen], leuprolide 
[gonadotropin-releasing hormone agonist], and raloxifene [estrogen agonist]); 3) retinoids (acitretin [RAR 
agonist], and bexarotene [RXR agonist]); 4) monoamine endocrine signaling molecules (doxylamine [anti-
histamine], dihydroergotamine [serotonin receptor agonist], metaclopramide [dopamine receptor 
antagonist]); 5) vitamin metabolism (folic acid, and warfarin [inhibitor of vitamin K epoxide reductase]); 6) 
antibiotic agents (ribavirin [anti-viral], and nystatin [anti-fungal]); 7) immunomodulatory agents 
(thalidomide [antiangiogenesis and immunomodulator], and misoprostol [prostaglandin E]); 8) a 
chemotherapeutic (fluorouracil [antimetabolite]); and 9) an antiarrhythmic (dronedarone [Na+ channel 
blocker]). These drugs were also evaluated for their impact on proliferation of P19C5 (embryonic) and 
NIH/3T3 (somatic) cells to assess general cytotoxicity of the test drugs. The present study shows a strong 
correlation between the in vitro effects and expected developmental toxicity of the drugs, which provides 
the crucial information on applicability and limitations of the P19C5 EB system as an in vitro assay for 
developmental toxicants. 
2.2 - Materials and methods 
2.2.1 CELL CULTURE AND EMBRYOID BODY FORMATION 
P19C5 cells (Lau and Marikawa, 2014) were maintained in the P19 culture medium (Minimum 
Essential Medium α, nucleosides, GlutaMAX Supplement [LifeTechnologies, Carlsbad, CA], 2.5% fetal 
bovine serum, 7.5% newborn calf serum, 50 units/mL penicillin, and 50 μg/mL streptomycin) and 
passaged every two days when cells had achieved 80-90% confluence in the culture flask. NIH/3T3 cells 
were obtained from the American Type Culture Collection (Manassas, VA), maintained in the 3T3 culture 
medium (Dulbecco’s Modified Eagle Medium, GlutaMAX Supplement [LifeTechnologies], 10 % fetal 
bovine serum, 50 units/mL penicillin, and 50 μg/mL streptomycin) and passaged every two days. 
Embryoid bodies (EBs) of P19C5 cells were generated in hanging drops of the culture medium 
supplemented with 1% dimethyl sulfoxide (DMSO), as previously described (Marikawa et al., 2009; Lau 
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and Marikawa, 2014). Briefly, P19C5 cells were fully dissociated with Trypsin-EDTA and suspended in the 
culture medium containing 1% DMSO at a density of 10 cells/μL. Drops (20 μL each) of cell suspension 
were deposited on the inner surface of Petri dish lids for hanging drop culture. All cells and EBs were 
cultured at 37°C in 4.5% CO2 in humidified air. 
2.2.2 DRUGS 
All drugs used in the study were purchased from Sigma-Aldrich (St. Louis, MO; lovastatin 
[PHR1285], metoclopramide monohydrochloride [M0763], ribavirin [R9644], dronedarone hydrochloride 
[D9696], leuprolide acetate [L0399], 5-fluorouracil [F6627], orlistat [O4139], doxylamine succinate 
[D3775], nystatin [N4014] and folic acid [F7876]) or from Santa Cruz Biotechnology (Dallas, TX; acitretin 
[sc-21075], misoprostol [sc-201264], mifepristone [sc-20126], bicalutamide [sc-202976], diethylstilbestrol 
[sc-204720], bexarotene [sc-217753], raloxifene hydrochloride [sc-204230], dihydroergotamine 
methanesulfonate [sc-294343], warfarin sodium [sc-204941] and thalidomide [sc-201445]). All drugs were 
dissolved in DMSO at 10 mM concentration and stored at -20°C. 
2.2.3 CELL VIABILITY ASSAY 
The impact of drugs on cell proliferation and viability was evaluated using CellTiter-Glo 
Luminescent Cell Viability Assay system, which determines the number of live cells in culture by 
measuring the amount of ATP as a quantitative proxy for the number of metabolically active cells 
(Promega, Madison, WI). P19C5 cells and NIH/3T3 cells were seeded in 96-well plates at the density of 
100 cells/well and 250 cells/well, respectively, and were cultured in the corresponding medium (100 
μL/well) supplemented with 1% DMSO containing serial dilution of the test drug (0.1, 1, 10, and 100 μM) 
or vehicle only as a control. After 4 days of culture, cells were treated with CellTiter-Glo Reagent for 
measurement of luminescence, as a readout of ATP amount, according to the manufacturer’s instruction 
(Promega), using Gene Light 55 Luminometer (Microtech, Chiba, Japan). Cell seeding density was 
optimized through a series of pilot experiments, to confirm that cell numbers at the end of 4 days of 
culture were proportionate to intensities of luminescence. Relative cell number was calculated based on 
ratio of the luminescence intensity in drug-treated cells to that in the control of the same set of 
experiments. For each drug, four sets of experiments were conducted as biological replicates, and the 
results were presented as mean ± standard deviation. 
2.2.4 MORPHOMETRIC PARAMETERS 
The experimental scheme to test drug impact on EB development is shown in Figure 1D. Each 
set of experiment consisted of five plates of hanging drops prepared using the same cell suspension: one 
control plate with no drug and four plates treated with serial dilutions of the test drug (0.1, 1, 10, and 100 
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μM). Each plate contained 16 hanging drops, which were cultured for four days after initial treatment 
without medium change. Survival and overall integrity of EBs were monitored on Days 1, 2, and 3. On 
Day 4, EBs were removed from hanging drops and placed together in a Petri dish filled with phosphate-
buffered saline for photography. Images were captured with AxioCam MRm digital camera (Carl Zeiss, 
Thornwood, NY) attached to Axiovert 200 inverted microscope with Hoffman modulation contrast optics 
(Carl Zeiss) and controlled by AxioVision software (Carl Zeiss). AxioVision image files were converted to 
JPG format, which were then opened in ImageJ program (http://rsb.info.nih.gov/ij) for morphometric 
analyses. The circumference of individual EBs was manually traced using the Polygon selections tool to 
measure the area and circularity (under shape descriptors). In the present study, the area was used to 
approximate the overall size of EBs. Elongation Distortion Index (EDI) expresses the extent of axial 
elongation and is calculated as (1/[circularity] -1), which is equivalent to the formula ([EB 
perimeter]2/4π[EB area] – 1), as described previously (Marikawa et al., 2009). Area and EDI were 
normalized by the average values of control EBs in each set of experiments to calculate relative EB size 
and relative EDI, respectively. Three sets of experiments were conducted for each drug as biological 
replicates, and all relative EB size and relative EDI were compiled and presented as mean ± standard 
deviation. 
2.2.5 STATISTICS 
Statistical differences were assessed by two-sample t-test. For cell viability assay, relative cell 
numbers of P19C5 cells from 4 experiments (n = 4) were compared with relative cell numbers of NIH/3T3 
cells from 4 experiments (n = 4) for each concentration of each drug tested. For EB morphogenesis, 
relative EDI of drug-treated EBs (n = 45 to 48, compiled from 3 experiments) were compared with relative 
EDI of control EBs (n = 45 to 48). Differences in average values were deemed significant when p values 
were less than 0.01. 
2.2.6 EXPERIMENTAL DESIGN 
Two types of assays were performed to evaluate the impact of the selected 20 drugs at four 
different concentrations (0.1, 1, 10, and 100 μM). The first assay was to examine drug impact on 
proliferation of P19C5 and NIH/3T3 cells. Cells were cultured for 4 days as mono-layer at a low density 
(to minimize contact inhibition) in the presence of test drugs, followed by measurement of total live cell 
number (see above). Relative cell number of drug-treated cells was normalized by the number of control 
cells that were cultured for 4 days in the absence of drug. This assay served two purposes: 1) to 
determine general cytotoxicity and 2) to assess selective inhibition of embryonic cell proliferation. 
“General cytotoxicity” was defined in the present study as a reduction in relative cell number of NIH/3T3 
cells below 20% of control. The rationale for this definition is as follows. Normal NIH/3T3 cells divide 
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approximately every 20 hours, and therefore they divide an average of 4.8 rounds during 4 days of 
culture, which increases cell number by ≈ 27.9-fold (= 2 4.8). If a half of cell divisions are inhibited during 
this period, cell number increases only by ≈ 5.3-fold (= 2 2.4), which is approximately 20% or less of 
control cells (= 5.3/27.9). Any drug concentrations that displayed general cytotoxicity were not considered 
“developmentally toxic” in the present study, regardless of other impacts that are described below. The 
second purpose of the assay was to assess whether a drug diminishes proliferation of P19C5 cells 
(representing embryonic cells) more strongly than NIH/3T3 cells (representing somatic cells). This was 
determined by comparing relative cell numbers between P19C5 and NIH/3T3 cells for each drug 
treatment. In the present study, significant reduction in P19C5 cell number relative to NIH/3T3 cell 
number was defined as a sign of selective adverse impact on embryonic cell proliferation. 
The second assay examined drug impact on growth and morphogenesis of P19C5 EBs. After 4 
days of hanging drop culture in the presence of test drugs, area and EDI were measured as 
morphometric parameters to assess EB growth and morphogenesis, respectively. In the present study, a 
reduction in EB size by more than 20% was classified as an adverse drug impact on EB growth. A 
significant decrease or increase in EDI was classified as an impact on EB morphogenesis. Although 
mechanistic causes of EDI decreases are likely to be different from EDI increases (see Discussion), both 
were grouped together as morphogenetic impact in the present study. 
Thus, if a drug caused “stronger inhibition of P19C5 proliferation”, “reduction in EB size”, and/or 
“decrease/increase in EDI” at concentrations that are not “generally toxic”, it was categorized as a 
developmental toxicant in the present study. Furthermore, if a drug displayed any of these effects at the 
lowest concentration tested (i.e., 0.1 μM), it was considered to have “high potency”. In contrast, the 
effects observed only at higher concentrations (i.e., 1, 10, and/or 100 μM) were considered to have “mild 
potency”. 
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2.3 - Results 
2.3.1 TIME COURSE OF GROWTH AND AXIAL ELONGATION MORPHOGENESIS IN P19C5 EBS 
During four days of hanging drop culture, P19C5 EBs steadily grew in size, which was 
quantitatively measured using EB area as a morphometric parameter (Fig. 2.1A, B). The overall shape of 
EBs was spherical during the first two days of culture (Days 1 and 2) but became ellipsoidal by the third 
day (Day 3) and distinctly elongated by the fourth day (Day 4; Fig. 2.1A). This temporal change in EB 
shape was quantified using another morphometric parameter, Elongation Distortion Index (EDI; see 
Materials and Methods), which significantly increased from Day 2 to Day 3 and from Day 3 to Day 4 (Fig. 
2.1C). In the following assessment of drug impact on EBs, the area and EDI were measured on Day 4 to 
assess overall growth and morphogenesis of EBs. 
2.3.2 DRUGS THAT IMPACTED P19C5 CELLS WITH HIGH POTENCY 
Eight out of the 20 drugs evaluated demonstrated high potency because they impacted P19C5 
proliferation and/or EB development at treatment concentrations as low as 0.1 µM. Highly potent drugs 
included acitretin, bexarotene, diethylstilbestrol, dronedarone, fluorouracil, mifepristone, raloxifene, and 
ribavirin. Acitretin is a synthetic retinoid that activates retinoic acid receptors and is prescribed for 
treatment of various skin diseases. Acitretin exhibited general cytotoxicity (i.e., NIH/3T3 cell number < 
20%) at 100 μM, which was also reflected in death of P19C5 cells in mono-layer culture as well as in 
hanging drops by Day 1. At lower concentrations (0.1, 1, and 10 μM), P19C5 cells aggregated into viable 
EBs and survived until Day 4, although they showed dramatic decreases in growth and morphogenesis 
(Fig. 2.2). Acitretin-treated EBs were markedly smaller than control EBs, with an average size less than 
50% of control. Additionally, acitretin-treated EBs retained the initial spherical shape void of any 
discernable elongation, as shown by marked reduction in EDI (Fig. 2.2 & Fig. 2.6A). 
Bexarotene, a synthetic retinoid that selectively targets retinoid X-receptors, is used to treat 
cutaneous T-cell lymphoma. Bexarotene at 100 μM exhibited general cytotoxicity along with death of 
P19C5 cells in hanging drops by Day 1. EBs were viable for 4 days of culture in other concentrations, but 
the EB size was markedly reduced. EDI was also significantly reduced by bexarotene at 1 and 10 μM 
(Fig. 2.2 & Fig. 2.6B). 
Diethylstilbestrol (DES) is a non-steroidal anti-estrogen and was historically prescribed to prevent 
miscarriages and premature deliveries. General cytotoxicity was observed at 100 μM, which 
corresponded to disintegration of P19C5 EBs by Day 3. EDI was slightly, but significantly increased by 
DES at 0.1 and 1 μM. DES at 10 μM also reduced the EB size by more than 20% (Fig. 2.2 & Fig. 2.6D). 
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Dronedarone is a multichannel blocker used to treat cardiac arrhythmia. Dronedarone at 10 and 
100 μM exhibited general toxicity and killed P19C5 cells in hanging drops by Day 1. Dronedarone caused 
significant reduction in P19C5 cell number relative to NIH/3T3 cells at 0.1 μM, but not at 1 μM (Fig. 2.2). 
No impact on EB development on size or EDI was observed at 0.1 μM or 1 μM (Fig. 2.6G). 
Fluorouracil is a pyrimidine analog antimetabolite and an antineoplastic agent used to treat 
various cancers. It was generally cytotoxic at 10 and 100 μM. At these concentrations of fluorouracil, EBs 
survived until Day 3 but completely disintegrated by Day 4. Significant reductions in P19C5 cell number 
and EB size were observed at 1 μM, but not at 0.1 μM. Notably, EDI was significantly increased by 
fluorouracil at 0.1 μM, and more markedly increased at 1 μM due to the drastically skinny shape of EBs 
(Fig. 2.3, Fig. 2.6H). 
Mifepristone is a synthetic steroid that inhibits progesterone receptor and is used as an 
abortifacient. It exhibited general toxicity at 100 μM, which also killed P19C5 cells in hanging drops by 
Day 1. The EB size was significantly reduced by mifepristone at 10 μM. Interestingly, EDI was 
significantly increased by mifepristone at 0.1 μM but decreased at 10 μM (Fig. 2.2 & Fig. 2.6M). 
Raloxifene is a selective estrogen receptor modulator prescribed to prevent osteoporosis in 
postmenopausal women. General cytotoxicity was observed at 100 μM, which also killed P19C5 cells in 
hanging drops by Day 1. Similarly to mifepristone, EDI was significantly increased at 0.1 μM but 
decreased at 10 μM (Fig. 2.2 & Fig. 2.6Q). EB growth was markedly diminished at 10 μM (Fig. 2.2). 
Ribavirin is a purine RNA analog used as an antiviral agent. Ribavirin exhibited general 
cytotoxicity at 100 μM. However, EB growth was only mildly impaired by ribavirin at 100 μM (Fig. 2.2 & 
Fig. 2.6R). Interestingly, EDI was altered by ribavirin at all concentrations tested, showing a significant 
increase at 0.1 μM, but decreases at 1, 10, and 100 μM (Fig. 2.2 & Fig. 2.6R). 
2.3.3 DRUGS THAT IMPACTED P19C5 CELLS WITH MILD POTENCY 
Seven drugs showed mild (i.e., at 1 μM or higher) impacts on P19C5 proliferation and/or EB 
development, including bicalutamide, dihydroergotamine, doxylamine, lovastatin, misoprostol, nystatin 
and orlistat. Bicalutamide is a non-steroidal anti-androgen used to treat prostate cancer and hirsutism. 
General cytotoxicity was observed at 100 μM (Fig. 2.3). At 10 μM, bicalutamide caused significant 
increase in EDI (Fig. 2.3 & Fig. 2.6C). 
Dihydroergotamine is semi-synthetic ergot alkaloid used to treat migraine headaches and 
orthostatic hypotension. General cytotoxicity was observed at 100 μM, which also killed P19C5 cells in 
hanging drops by Day 1. Dihydroergotamine at 10 μM concentration reduced both P19C5 cell number 
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and EB growth but promoted NIH/3T3 cell proliferation. Dihydroergotamine did not show significant 
impact on EDI (Fig. 2.3 & Fig. 2.6E).  
Doxylamine is a first generation anti-histamine used to treat respiratory allergies. At the highest 
concentration (100 μM), doxylamine promoted NIH/3T3 cell proliferation, but it caused a slight reduction 
in P19C5 cell number. At 100 µM concentration, EDI was also significantly decreased, without any 
observable impact on EB size (Fig. 2.3 & Fig. 2.6E). 
Lovastatin is a competitive HMG-CoA reductase inhibitor used to reduce LDL-cholesterol levels in 
hypercholesterolemia. Lovastatin was generally cytotoxic at 10 and 100 µM. Treatment concentrations of 
1 µM caused a reduction in EB size (< 80% of control). Notably, although no significant change in EDI 
was observed at 1 µM, the EDI standard deviation was markedly larger than the EDI standard deviation of 
the control (Fig. 2.3), suggesting that lovastatin caused more variability in EB shapes (Fig. 2.6K). 
Misoprostol is synthetic prostaglandin E1 analog used to prevent gastric ulcers induced by non-
steroidal anti-inflammatory drugs. It exhibited general cytotoxicity at 100 μM. At 10 μM, misoprostol 
caused reductions in P19C5 cell number relative to NIH/3T3 and diminished EB size. Significant increase 
in EDI was also observed at this concentration (Fig. 2.3 & Fig. 2.6N). 
Nystatin binds to cell membrane ergosterol and is used as an antifungal medication. Nystatin did 
not exhibit general cytotoxicity at any of the concentrations tested. However, a reductions in both EB size 
and EDI were observed at 100 μM (Fig. 2.3 & Fig. 2.6O). 
Orlistat is a lipase inhibitor used to treat or prevent obesity. Orlistat reduced P19C5 cell number 
more significantly than NIH/3T3 at 100 μM and caused significant reductions in EB size and EDI (Fig. 2.3 
& Fig. 2.6P). 
2.3.4 DRUGS THAT DID NOT EXHIBIT ANY IMPACT 
The following 5 drugs did not display general cytotoxicity or show observable impact on P19C5 
cells at the concentrations tested: folic acid (vitamin B9,a dietary supplement), leuprolide (a growth 
hormone-releasing hormone [GnRH] receptor agonist and inhibits gonadotropin secretion from the 
pituitary gland), metoclopramide (an antagonist of dopamine and serotonin receptors used as an 
antiemetic), thalidomide (an immunomodulatory agent), and warfarin (a vitamin K epoxide reductase 
inhibitor used as an anticoagulant) (Fig. 2.4 & Fig. 2.6I, J, L, S, and T). 
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2.3.5 CORRELATION BETWEEN DRUG IMPACT ON P19C5 CELLS AND KNOWN PREGNANCY 
RISKS 
The overall effects of the 20 drugs evaluated in the present study are summarized in Figure 5. 
Thirteen of the 16 contraindicated drugs impacted proliferation, EB growth and/or morphogenesis of 
P19C5 cells, with high or mild potency. Notably, all of the highly potent drugs (acitretin, bexarotene, DES, 
dronedarone, fluorouracil, mifepristone, raloxifene, and ribavirin) are contraindicated. Of the seven drugs 
that mildly impacted P19C5 cells, 5 are contraindicated (bicalutamide, dihydroergotamine, lovastatin, 
misoprostol, and orlistat) while 2 (doxylamine and nystatin) are considered safe for use during pregnancy. 
The impact of these safe drugs was observed only at the highest concentration (100 μM). All of the 
contraindicated drugs with mild impact, with the exception of orlistat, exhibited effects at concentrations 
lower than 100 μM. Also, although orlistat displayed significant impact only at 100 μM, it affected all three 
parameters of treated P19C5 cells, proliferation, EB size, and EDI. In contrast, doxylamine and nystatin 
impacted only two aspects parameters. Therefore, the two assays employed in the present study 
demonstrated a strong correlation between in vitro impact and known pregnancy risks of the drugs. 
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2.4 - Discussion 
To reduce animal use in developmental toxicology studies, in vitro alternatives are strongly 
desired. Because only a limited aspect of in vivo processes can be simulated in a single type of in vitro 
test, multiple tests would be required to encompass a broad range of embryonic events. Here, we 
explored the potential of P19C5 EBs, which simulate growth and axial elongation morphogenesis of early 
embryos, as an in vitro tool to study human developmental toxicants. The analysis measured 
morphometric parameters (size and EDI) of Day 4 EBs to evaluate developmental impact of 20 
therapeutic drugs with known in vivo developmental toxicity in humans (Table 2.1). The morphometric 
analysis was paired with cytotoxicity data obtained from proliferation assays of embryonic P19C5 cells 
and of somatic NIH/3T3 fibroblast cells. To our knowledge, this is the first study to incorporate the 
morphogenesis of EBs as a stem cell-based in vitro test for developmental toxicants. Although the 
effectiveness of P19C5 EB morphogenesis system needs to be further examined using a wider array of 
chemical compounds with known developmental toxicity, the present study serves as an introduction for a 
novel in vitro test that will complement other non-animal alternative methods. 
Recently, another research group has shown that EBs made of mouse ES cells (mESC) also 
display axial elongation morphogenesis reminiscent of gastrulating embryos (van den Brink et al., 2014). 
This indicates that in vitro recapitulation of morphogenesis is not a property exclusive to P19 and P19C5 
cells. An in vitro gastrulation model of mESC may be incorporated for developmental toxicity tests in 
future studies. Nonetheless, elongation morphogenesis appears to occur more easily and prominently in 
P19C5 EBs compared to mESC EBs. To generate elongating EBs, mESCs are first aggregated in 
hanging drops for 2 days, before being transferred to a non-adhesive Petri dish filled with a culture 
medium containing activators of Nodal signaling (Activin A) and Wnt signaling (CHIR99021; a 
pharmacological inhibitor of glycogen synthase kinase 3) to induce mesendoderm formation. After 
exposure to these activators, EBs begin to elongate within 2-3 days (van den Brink et al., 2014). In 
contrast, P19 and P19C5 EBs spontaneously elongate in hanging drops without a change of culture 
format or addition of Nodal and Wnt activators. The difference between mESC and P19 cells’ ability to 
initiate gastrulation may be due to the difference in the developmental stages represented by these two 
pluripotent stem cell lines. mESCs retain developmental and molecular properties that are close to the 
inner cell mass or the epiblast of the pre-implantation embryo, whereas P19 cells possess features of the 
primitive ectoderm or the epiblast of the post-implantation embryo (Jones-Villeneuve et al., 1982; Yeom et 
al., 1996; Niwa, 2007). Use of multiple stem cell lines representing different developmental stages is likely 
to enhance studies of developmental toxicants, because actions of chemical agents may differ depending 
on embryonic stages. Regardless, the relatively simple protocol to induce morphogenesis in P19C5 EBs 
offers a practical benefit by reducing the time and labor required to induce gastrulation. 
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One of the most challenging aspects of developing and validating in vitro systems for 
developmental toxicity tests is the selection of test drugs. Many efforts have been made to choose a 
suitable list of reference compounds to be used for the validation of in vitro as well as non-mammalian 
test systems. Examples of validation panels include the group of 20 compounds selected under the 
direction of the European Centre for the Validation of Alternative Methods (ECVAM) (Brown et al., 2002) 
and the additional 13 compounds chosen for follow-up studies (Marx-Stoelting et al., 2009). Although 
these compounds were selected carefully based on available, high-quality in vivo data, it is controversial 
as to whether they can serve as “gold standards” for validation of in any vitro systems (Daston et al., 
2010, 2014; Riebeling et al., 2012). In the present study, we selected 20 drugs with diverse chemical and 
therapeutic properties in order to gain insight into the applicability and limitation of P19C5 EBs to detect 
developmental toxicants. Although these drugs were selected independently from the previously chosen 
reference compounds for the other studies, there were some overlaps with the 13 follow-up compounds 
mentioned above, namely lovastatin, warfarin, doxylamine, and metoclopramide. Nonetheless, it is clear 
that further investigations are necessary using additional compounds to more fully reveal the strengths 
and weaknesses of each in vitro system. 
Because most embryonic events, including cell differentiation and morphogenesis, are tightly 
regulated by the actions of specific gene products, incorporation of molecular endpoint analysis is likely to 
allow more effective detection of developmental toxicity. Indeed, various molecular endpoints, particularly 
involving detection of cell type-specific gene expression, have been incorporated into ESTs, so that 
chemical impact on cell differentiation can be assessed more sensitively, quantitatively, objectively, and 
speedily (zur Nieden et al., 2001; Buesen et al., 2004, 2009; Seiler et al., 2004; Suzuki et al., 2011; Seiler 
and Spielmann, 2011; van Dartel and Piersma, 2011; de Jong et al., 2012; Hayes et al., 2013; Panzica-
Kelly et al. 2013; Gao et al., 2014; Li et al., 2015). P19C5 EB system is also amenable to the addition of 
molecular endpoint analyses. Previously, we showed that the Alzheimer’s medication, donepezil, 
diminishes EB elongation. While the morphogenetic impact of donepezil was detectable in Day 4 EBs as 
a significant reduction in EDI, the expressions of developmental regulator genes, such as Fgf8 and Cdx2, 
were significantly altered by donepezil in Day 2 EBs (Lau and Marikawa, 2014). In P19 and P19C5 EBs, a 
number of developmental regulator genes for gastrulation and axial patterning, such as Brachyury, Snai1, 
Wnt3a, Notch1, and Hox genes, are expressed in a temporally and spatially specific manner (Marikawa et 
al., 2009; Lau and Marikawa, 2014). Thus, future investigations incorporating gene expression analyses 
should provide deeper insight into potential developmental toxicity of various chemical agents and their 
mechanisms of action. 
P19C5 EB morphogenesis simulates only a limited stage and a limited region of embryo 
development. The temporal profile of gene expressions (Marikawa et al., 2009; Lau and Marikawa, 2014) 
suggests that the four days of P19C5 EB development represent E5.0 to E8.0 of mouse embryonic 
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stages, which roughly correspond to the second through fourth weeks of human development. Also, 
based on the spatial profile of gene expressions, P19C5 EBs appear to represent the caudal region of the 
embryo, but not the cranial structures, such as the brain and the heart. Nonetheless, many of the 
contraindicated drugs affected P19C5 EB development in the present study. It is possible that numerous 
developmental regulators that also play essential roles in other stages and regions of embryo 
development control P19C5 EB morphogenesis. Elongation morphogenesis of P19C5 EBs depends on 
various core developmental signals, specifically Wnt, Nodal/Activin, Bmp, Fgf, and retinoic acid pathways, 
which alters EB morphogenesis in a manner consistent with their roles in gastrulation and axial elongation 
and patterning in vivo (Marikawa et al., 2009; unpublished data). Chemicals that interfere with these 
signals are likely to impair P19C5 EB morphogenesis. Apart from the synthetic retinoids, acitretin and 
bexarotene, it is currently unknown whether the contraindicated drugs tested in the present study 
influence the above signaling pathways. However, genetic studies have linked anomalies in these 
signaling pathways to numerous human birth defects; for example, Wnt signaling is implicated in tetra-
amelia and congenital duplication of palm syndrome (Niemann et al., 2004; Al-Qattan et al., 2009), 
Nodal/Activin signaling is linked to heterotaxy syndrome (Ma et al., 2012), and Fgf signaling is associated 
with achondroplasia and Apert syndrome (Yamaguchi and Rossant, 1995; Hajihosseini, 2008). Thus, in 
spite of a limited representation of developmental events, P19C5 EB morphogenesis may be more 
versatile in detecting a wide range of developmental toxicants. 
In the present study, size and EDI were used as morphometric parameters of EBs to 
quantitatively measure developmental impact of drugs. EDI is calculated based on the size (area) and the 
length of circumference (perimeter) of individual EBs, and its increase implicates more elongation and/or 
distortion of the EB shape. EB elongation is driven by convergent extension, a morphogenetic process of 
orchestrated cell migration and intercalation (Tada and Heisenberg, 2012). Thus, reduction in EDI may be 
caused by impairment in convergent extension, which is likely to contribute to developmental anomalies 
in vivo, including neural tube defects (Copp et al., 2003; Ueno and Greene, 2003). In contrast, the 
mechanistic basis for an increase in EDI is currently unclear, although stimulated cell migration or 
reduced surface tension may cause pronounced elongation or distortion of EBs. Further investigations 
are required to elucidate the cellular and molecular mechanisms that are behind increased EB elongation 
or distortion. Also, EDI alone is not sufficient to distinguish between elongation and distortion effectively. 
Thus, in addition to EDI, other morphometric parameters need to be explored in future studies to detect 
various morphogenetic impacts on EBs.  
Three of the contraindicated drugs (leuprolide, thalidomide and warfarin) did not alter EB size or 
EDI, whereas two safe drugs (doxylamine and nystatin) impaired EB development at the highest 
concentration (100 μM). These five cases of apparent “misclassifications” may exemplify limitations of the 
P19C5 model in predicting certain developmental toxicants. Like most other in vitro tests, the P19C5 EB 
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system recapitulates only embryological events, but not maternal environment. Thus, it is unlikely to 
detect developmental toxicants that primarily act on maternal tissues and indirectly disturb embryo 
development. This may be the case for leuprolide, which primarily acts on the maternal pituitary gland 
and alters the levels of endocrine hormone signaling to secondarily impair embryogenesis. Furthermore, 
most in vitro systems, including P19C5 EBs, are limited by a reliance on an artificial culture environment, 
which may obscure the effects of certain drugs. Developmental toxicity of warfarin is likely due to its 
action as an inhibitor of vitamin K regeneration. Animal serum in the P19C5 culture medium may contain 
a substantial amount of vitamin K, which may negate the effects of warfarin. Because most culture media, 
supplements and sera are enriched with various essential metabolites, results of in vitro toxicity tests, 
particularly those with no impact, may require cautious interpretation with consideration of mechanisms of 
drug action. 
Developmental toxicants that exhibit species-specific effects may also be misclassified by the 
P19C5 system, which is composed of mouse stem cells. Although thalidomide is a well-known teratogen 
in humans, the limb malformations characteristic of thalidomide-induced developmental toxicity are 
essentially absent in rodents (Brent, 1964). Thalidomide binds and inhibits the cereblon protein, which 
appears to be the primary cause of its teratogenic effects (Ito et al., 2010). However, homozygous 
cereblon-knockout mice exhibit only behavioral problems with no limb defects (Rajadhyaksha et al., 
2012). Thus, failure of thalidomide to impact P19C5 morphogenesis may be reflective of species-specific 
teratogenicity. To detect developmental toxicants that specifically affect human embryos, in vitro 
morphogenesis models composed of human cells may be necessary. Many researchers have adopted 
human ES cells (hESC) as more human-relevant in vitro models to assess developmental toxicity of 
chemical agents, and some hESC systems have been shown to detect the effect of thalidomide 
(Kameoka et al., 2014; Xing et al., 2015). Previously, we established a culture condition to induce 
elongation morphogenesis in EBs made of hESCs (Lau and Marikawa, 2014). It is of particular interest to 
examine whether thalidomide affects morphogenesis of these hESC EBs in future studies. 
Although considered safe to be used during pregnancy, both doxylamine and nystatin impaired 
P19C5 EB development. This apparent misclassification highlights another limitation of the experimental 
scheme that was adopted in the present study, i.e., methodical testing of a set of predetermined 
concentrations. The concentration range of 0.1 to 100 µM may not reflect realistic levels of exposure of 
certain drugs to the developing human embryo. As an antifungal agent, nystatin is administered topically 
or orally and is minimally absorbed into circulation. Thus, the chance of embryonic exposure to high 
levels of nystatin is negligible, which likely contributed to the low pregnancy risk classification of this drug. 
However, nystatin is also known to be highly toxic when administered intravenously. The adverse impact 
on EB development may have been reflecting the toxic potential of nystatin at high plasma 
concentrations, which are unlikely to occur in pregnant women who use nystatin only topically or orally. 
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Also, the concentration of doxylamine that affected P19C5 cell number and EDI was 100 µM, which is far 
higher than the plasma concentration found after routine doses in patients (Videla et al., 2013). Therefore, 
in future studies to validate the P19C5 EB system, it is important to consider realistic exposure levels for 
each drug — a concept that is extensively discussed in recent studies by Daston et al. (2010, 2014) as a 
critical feature of effective developmental toxicant assays. 
As a potential tool for developmental toxicity testing, the P19C5 EB system has several practical 
advantages over other in vitro methods. First, the P19C5 system requires only four days from the start of 
hanging drop culture to morphometric analysis. In contrast, the standard ESTc protocol requires a total of 
10 days of culture to observe beating of cardiomyocytes (Spielmann et al., 1997; Seiler et al., 2006). 
Modifications of ESTc have shortened the duration of the assay by analyzing specific cardiac marker 
gene expression, but still require six days of culture (Suzuki et al., 2011). Secondly, the procedure for 
P19C5 EB culture is simple, as it takes only one series of hanging drop culture without any change of 
culture medium or culture format. This is an advantage over other EST protocols that require changes in 
culture medium and/or format in order to promote differentiation of specific cell types. Thirdly, simple 
tracing of EB circumferences in the ImageJ program can provide data on multiple morphometric 
parameters, including the size and EDI, which are altered by developmental toxicity of test compounds. 
Each morphometric parameter is likely to be affected by specific aspects of EB development. For 
example, changes in cell proliferation would impact EB size whereas alteration in cell migration and 
adhesion would affect EDI. Thus, morphometric analyses can provide mechanistic insight into the action 
of developmental toxicants without intensive labor or techniques. Lastly, the P19C5 EB system may be 
more economical. Culturing the P19C5 cell line is less expensive than culturing ES cell lines because it 
does not require supplementation of Leukemia Inhibitory Factor for the maintenance of undifferentiated 
state. Furthermore, drug impact in the P19C5 system can be assessed visually using the ImageJ 
program, which is freely available from the National Institutes of Health. These practical advantages do 
not presume effectiveness or applicability of the P19C5 EB systems. However, the establishment of 
faster, simpler, and cheaper methods is necessary for pharmaceutical companies to conduct thorough 
and extensive developmental toxicity tests on the hundreds or thousands of new therapeutic compounds. 
Though further validation studies are needed, the present study shows that the P19C5 EB system 
is a promising non-animal test for developmental toxicants, because it has potential of high accuracy, 
offers economic practicality, and is based on realistic embryologic processes of growth and 
morphogenesis that are often targeted in various birth defects. 
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Figure 2.1. In vitro morphogenesis of P19C5 embryoid bodies (EBs). (A) Photographs of control EBs over 
four days of culture to demonstrate the time course of morphological transformation. Scale bar = 500 μm. 
(B, C) Temporal changes in the EB size (B) and EDI (C). Graphs are mean + standard deviation (n = 44). 
Asterisks indicate significant differences between two adjacent groups (p < 0.01; two-sample t-test). (D) 
The experimental scheme to examine morphogenetic impact of the therapeutic drugs.  
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Figure 2.2. Drugs that impacted P19C5 cells with high potency. Three types of graphs are shown for 
each drug. Relative values are calculated as a percentage of the corresponding set’s control value. All 
control values are shown as 100. Top: Relative cell numbers of P19C5 (red line) and NIH/3T3 (blue line) 
after 4 days of mono-layer culture in the presence of drug. Mean ± standard deviation is presented for 
each cell line (n = 4). Downward black arrows indicate significant reductions in P19C5 cell number 
relative to NIH/3T3 cell number (p < 0.01). Middle: Relative size of P19C5 EBs after 4 days of hanging 
drop culture in the presence of drug. Mean ± standard deviation is presented as the data points and error 
bars respectively (n = 45 to 48). Values of “0” for relative EB size indicate death of EBs. Bottom: Relative 
EDI (Elongation Distortion Index) of P19C5 EBs after 4 days of hanging drop culture. Mean + standard 
deviation is presented as each column’s height and error bar respectively (n = 45 to 48). Downward black 
arrows indicate significant reductions in relative EDI whereas upward white arrows indicate significant 
increase in relative EDI (p < 0.01). NA: Not applicable due to death of EBs. Horizontal axes represent 
drug concentrations in micromolar.  
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Figure 2.3. Drugs that impacted P19C5 cells with mild potency. Relative values are calculated as a 
percentage of the corresponding set’s control value, and all control values are shown as 100. Top: 
Relative cell numbers of P19C5 (red line) and NIH/3T3 (blue line) after 4 days of mono-layer culture in the 
presence of drug. Mean ± standard deviation is presented for each cell line (n = 4). Downward black 
arrows indicate significant reductions in P19C5 cell number relative to NIH/3T3 cell number (p < 0.01). 
Middle: Relative size of P19C5 EBs after 4 days of hanging drop culture in the presence of drug. Mean ± 
standard deviation is presented as the data points and error bars respectively (n = 45 to 48). Bottom: 
Relative EDI (Elongation Distortion Index) of P19C5 EBs after 4 days of hanging drop culture. Mean + 
standard deviation is presented as each column’s height and error bar respectively (n = 45 to 48). 
Downward black arrows indicate significant reductions in relative EDI whereas upward white arrows 
indicate significant increase in relative EDI (p < 0.01). NA: Not applicable due to death of EBs. Horizontal 
axes represent drug concentrations in micromolar. 
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Figure 2.4. Drugs that did not impact P19C5 cells. Top: Relative cell numbers of P19C5 (red line) and 
NIH/3T3 (blue line) after 4 days of mono-layer culture in the presence of drug. Mean ± standard deviation 
is presented for each cell line (n = 4). Middle: Relative size of P19C5 EBs after 4 days of hanging drop 
culture in the presence of drug. Mean ± standard deviation is presented (n = 45 to 48). Bottom: Relative 
EDI (Elongation Distortion Index) of P19C5 EBs after 4 days of hanging drop culture. Mean + standard 
deviation is presented (n = 45 to 48). Horizontal axes represent drug concentrations in micromolar.  
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Figure 2.5. Summary diagram of drug impacts. See text for details. 
33 
 
Figure 2.6. Example images of P19C5 EBs after four days of treatment in hanging drop culture. 
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Figure 2.6. (Continued). Example images of P19C5 EBs after four days of treatment in hanging drop 
culture. 
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Figure 2.6. (Continued). Example images of P19C5 EBs after four days of treatment in hanging drop 
culture. 
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Figure 2.6. (Continued). Example images of P19C5 EBs after four days of treatment in hanging drop 
culture. 
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Table 2.1. Compounds used in the Category X validation study. 
Drug Name 
(CAS RN*1) 
Pregnancy Risk Therapeutic Target Chemical Properties References*2 
Acitretin (CAS 
55079-83-9) 
Contraindicated Dermatologic 
diseases 
Synthetic retinoid 
(RAR receptor 
agonist) 
Barbero et al., 2004; 
Geiger et al., 1994 
Bexarotene (CAS 
153559-49-0) 
Contraindicated Cutaneous T-cell 
lymphoma 
Synthetic retinoid 
(RXR receptor 
agonist) 
Lu et al., 1997; Elmazar 
and Nau, 2004 
Bicalutamide (CAS 
90357-06-5) 
Contraindicated Prostate cancer, 
Hirsutism 
Non-steroidal anti-
androgen 
Sadar et al., 1999; 
Cockshott, 2004 
Diethylstilbestrol 
(CAS 56-53-1) 
Contraindicated Miscarriage; 
Premature 
deliveries 
Non-steroidal 
estrogen 
Mahawong et al., 2014; 
Reed and Fenton, 2013 
Dihydroergotamine 
(CAS 511-12-6) 
Contraindicated Migraine Synthetic ergot 
alkaloid 
Bérard and Kori, 2012; 
Hohmann and Künzel, 
1992 
Doxylamine (CAS 
469-21-6) 
Safe Allergy First generation 
antihistamine 
Gilboa et al., 2014; 
Slaughter et al., 2014 
Dronedarone 
(CAS 141626-36-
0) 
Contraindicated Arrhythmia Multi-channel blocker  Marzocchi and 
Lombardi, 2011; Eskes 
and Wiersinga, 2009 
Fluorouracil (CAS 
51-21-8) 
Contraindicated Cancer Thymidylate synthase 
inhibitor 
Kuwagata et al., 1998; 
Murthy et al., 2014 
Folic Acid (CASRN 
59-30-3) 
Safe Used as dietary 
supplement 
Vitamin B9 van Mil et al., 2010; 
Charles et al., 2005 
Leuprolide (CAS 
53714-56-0) 
Contraindicated Endometriosis; 
Prostate cancer 
LHRH receptor 
agonist 
Abu-Heija et al., 1995; 
Cahill et al., 1994 
Lovastatin (CAS 
75330-75-5) 
Contraindicated Hyper-
cholesterolemia 
HMG-CoA reductase 
inhibitor  
Lankas et al., 2004 
Godfrey, 2012 
Metoclopramide 
(CAS 364-62-5) 
Safe Nausea Dopamine receptor 
antagonist 
Pasternak et al., 2013; 
Matok and Perlman, 
2014 
Mifepristone (CAS 
84371-65-3) 
Contraindicated Used as 
abortifacent 
Progesterone 
receptor antagonist 
Chen et al., 2014; 
Blanch et al., 1998 
Misoprostol (CAS 
59122-46-2) 
Contraindicated Gastric ulcers Prostaglandin E1 
analog 
Bos-Thompson et al., 
2008; Schüler et al., 
1999 
Nystatin (CAS 
1400-61-9) 
Safe Fungal infection Ergosterol-binding King et al., 1998; Larson 
et al., 2000 
Orlistat (CAS 
96829-58-20) 
Contraindicated Obesity Lipase inhibitor Källén, 2014; Browne et 
al., 2006 
Raloxifene (CAS 
84449-90-1) 
Contraindicated Osteoporosis; 
Breast cancer 
Selective estrogen 
receptor modulator 
Gizzo et al., 2013; 
Komm and Mirkin, 2014 
Ribavirin (CAS 
36791-04-5) 
Contraindicated Viral infection Purine analog Roberts et al., 2010; De 
Santis et al., 2003 
Thalidomide (CAS 
50-35-1) 
Contraindicated Leprosy; Multiple 
myeloma 
Immuno-modulatory 
agent 
Vargesson, 2009; Ito 
and Handa, 2012 
Warfarin (CAS 81-
81-2) 
Contraindicated Used as blood 
thinner 
Vitamin K epoxide 
reductase inhibitor 
Starling et al., 2012; 
Mehndiratta et al., 2010 
 
*1 CAS RN: Chemical Abstracts Service Registration Number 
 
*2 References that are relevant to pregnancy risk and/or mechanisms of actions 
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CHAPTER 3. EXPOSURE-BASED VALIDATION OF AN IN VITRO 
GASTRULATION MODEL FOR DEVELOPMENTAL TOXICITY ASSAYS 
3.1 - Introduction 
In utero exposure to developmental toxicants can interfere with the normal course of embryonic 
development and result in abnormalities, such as death, growth retardation and malformations. Many 
medications, herbicides and industrial byproducts are known to be developmental toxicants (Schardein 
and Macina, 2006). However, many more compounds have not been sufficiently evaluated for potential 
developmental toxicity, so that continued efforts are required to identify adverse impact on embryos and 
to minimize harmful exposures to women of child-bearing age. In vitro model systems, particularly those 
using pluripotent stem cells, are promising screening tools for developmental toxicants. Pluripotent stem 
cells, such as embryonic stem (ES) cells, can differentiate into multiple tissue types in vitro and display 
embryo-like properties. Thus, pluripotent stem cells can recapitulate certain aspects of embryonic 
development and serve as in vitro models to demonstrate the impacts of developmental toxicants. ES cell 
tests, or ESTs, evaluate the developmental toxicity of compounds based on their inhibitory effects on ES 
cell differentiation (Riebeling et al., 2012; Theunissen et al., 2012), but each individual EST system 
recapitulates only a limited aspect of embryonic development, i.e., differentiation of cardiomyocytes, 
neurons, or osteoblasts. Thus, it is more likely that a panel of complementary in vitro systems — each 
representing distinct aspects of embryonic development — can comprehensively screen a broad range of 
developmental toxicants. 
To assemble a panel of complementary assays, each assay must undergo a series of validation 
studies using known developmental toxicants to assess its applicability and limitations. However, 
selection of proper reference compounds to validate in vitro screening assays has been challenging, 
partly because developmental impact of compounds varies depending on timing, dose and duration of 
exposure to embryos (Friedman, 2010; Jelínek, 2005). For example, a given compound can exert 
developmental toxicity when exposed at a high dose, but the same compound may pose no risk at lower 
doses (Daston et al., 2010). Therefore, dichotomic designation of compounds as developmental toxicants 
or non-toxicants is ineffective in properly validating assays. To that end, Daston and colleagues have 
proposed an “exposure-based validation list” for developmental toxicity screening assays (Daston et al., 
2014). This list (referred hereafter as the Daston list) consists of 20 “positive exposures” known to cause 
embryo-fetal death or structural malformation in rats, and 19 “negative exposures”, which have no 
adverse impacts on rat embryo development. Eleven of these compounds demonstrate both a positive 
exposure at a high concentration and a negative exposure at a low concentration. The Daston list is a 
significant step forward in validating in vitro assays for developmental toxicity screening. 
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The objective of the present study is to validate the in vitro gastrulation model of P19C5 stem 
cells using the compounds on the Daston list. P19C5 cells are mouse embryonal carcinoma stem cells 
that possess properties similar to the pluripotent epiblast lineage of post-implantation embryos. Three-
dimensional culture of P19C5 cell aggregates results in spontaneous differentiation of mesendoderm 
along with steady increase in size and axial elongation (Lau and Marikawa, 2014). This morphogenetic 
transformation of P19C5 cell aggregates, or embryoid bodies (EBs), resembles gastrulation, the 
morphogenetic process of early embryonic development that creates the germ layers and elongated body 
shape along the anterior-posterior axis. Growth and axial elongation of the P19C5 gastrulation model are 
impaired by pharmacological inhibitors of the major developmental signals that are crucial for embryo 
body patterning, namely Wnt, Nodal, Fgf and retinoic acid signaling pathways (Li and Marikawa, 2015). 
The morphogenesis of P19C5 EBs is also sensitive to various therapeutic drugs under the Food and Drug 
Administration (FDA) Pregnancy Risk Category X, i.e., those contraindicated for use during pregnancy 
(Warkus et al., 2016). Furthermore, valproic acid (VPA) at 0.8 mM, one of the positive exposures in the 
Daston list, affects the P19C5 morphogenesis, such that VPA-treated EBs are smaller, distorted, and less 
elongated (Li and Marikawa, 2016). These studies suggest that the P19C5 gastrulation model can serve 
as an effective in vitro tool to detect developmental toxicants. 
Here, we validated the P19C5 gastrulation model using the 34 exposures compiled in the Daston 
list. While the morphology-based assay correctly classified many of the Daston exposures, the present 
study also revealed some limitations of the assay based on the cases where exposures were 
misclassified. 
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3.2 - Materials and methods 
3.2.1 TEST COMPOUNDS 
Compounds of the Daston list (Daston et al., 2014) used in the present study are shown in Table 
1. Four compounds in the Daston list, namely HEPP (positive exposure), SB-209770 (positive and 
negative exposures), tapentadol (negative exposure), and valproic acid (positive exposure), were not 
evaluated for the following reasons. HEPP and SB-209770 were unavailable from major chemical 
suppliers. Tapentadol was available from one supplier (Sigma-Aldrich, St Louis, Missouri) as a solution of 
1.0 mg/mL dissolved in methanol (Catalog Number T-058). However, to achieve the concentration 
indicated in the Daston list (252 mg/L), about 25% of the culture medium would be methanol, which is not 
compatible with our assay (see below). The morphogenetic effect of valproic acid on the P19C5 
gastrulation model has been evaluated previously, including the concentration cited in the Daston list (0.8 
mM) (Li and Marikawa, 2016). Note that the concentration of desloratadine indicated in the Daston study 
(1.5 mM) (Daston et al., 2014) is apparently a typographical error, as the original study referenced therein 
(FDA, 2001) indicates 1.5 μM instead. Accordingly, desloratadine was evaluated at 1.5 μM as a negative 
exposure in the present study. 
3.2.2 CELL CULTURE 
 P19C5 cells, a subline of P19 mouse embryonal carcinoma cell line (Lau and Marikawa, 2014), 
were propagated in culture medium (Minimum Essential Medium Alpha with nucleosides and GlutaMAX 
Supplement [LifeTechnologies, Carlsbad, California], 2.5% fetal bovine serum, 7.5% newborn calf serum, 
50 units/mL penicillin, and 50 μg/mL streptomycin). Embryoid bodies (EBs) of P19C5 cells were 
generated according to the method previously described for P19 cell aggregates (Marikawa et al., 2009). 
Briefly, P19C5 cells were fully dissociated with Trypsin-EDTA, and suspended in culture medium 
containing 1% dimethyl sulfoxide (DMSO) at the density of 10 cells/μL with or without specific amount of a 
test compound (Fig. 3.1). Drops (20 μL each) of cell suspension were spotted on the inner surface of Petri 
dish lids for hanging drop culture. NIH/3T3 (derived from mouse embryonic fibroblast), HEK293 (derived 
from human embryonic kidney), and JEG3 (derived from human choriocarcinoma) were obtained from the 
American Type Culture Collection (Manassas, Virginia), and propagated in culture medium (Dulbecco’s 
Modified Eagle Medium, GlutaMAX Supplement [LifeTechnologies], 10% fetal bovine serum, 50 units/mL 
penicillin, and 50 μg/mL streptomycin). 
3.2.3 IMAGE ANALYSIS 
Embryoid bodies (EBs) were removed from hanging drops and grouped together for photography 
using an AxioCam MRm digital camera connected to an Axiovert 200 microscope with Hoffman 
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modulation-contrast optics (Carl Zeiss, Thornwood, NY). Image files were converted to JPEG format and 
opened in ImageJ (http://rsb.infonihgov/ij). Morphological parameters of individual EBs were measured on 
ImageJ by tracing their circumference. In the previous studies (Lau and Marikawa, 2014; Li and 
Marikawa, 2015; Warkus et al., 2016), tracing of EB circumference was performed manually using the 
polygon selection tool. In the present study, however, we formulated a series of program operations to 
enable tracing of EB circumference in a faster and less laborious fashion. The details of the program 
operations are described in Appendices A and B. Briefly, the first set of operations (e.g., Image 
Calculator, Find Edges, Brightness/Contrast and Binary) was applied to convert the inside of EBs into 
solid black while the background into white. The second set of operations (e.g., Wand Tool and Fit 
Splines) was applied to detect the outlines of blackened areas, corresponding to the circumference of 
EBs. The third set of operations (e.g., Measure) was applied to selected regions of interest (ROI) to 
determine their morphological parameters, namely area and circularity (= 4 × π × area / perimeter2). 
Measurements were exported to Microsoft Excel, where Elongation Distortion Index (EDI = 1 / circularity − 
1) was calculated. As described previously, area was used as a proxy for the size of EB, whereas EDI 
was used to gauge the extent of EB axial elongation (Warkus et al., 2016). 
3.2.4 VIABILITY ASSAY 
The impact of drugs on cell proliferation and viability was evaluated using CellTiter-Glo 
Luminescent Cell Viability Assay system (Promega, Madison, Wisconsin), which determines the number 
of live cells in culture by measuring the amount of ATP as a quantitative proxy for the number of 
metabolically active cells. P19C5, NIH/3T3, HEK293 and JEG3 cells were seeded in 96-well plates at the 
density of 100, 250, 250 and 500 cells/well, respectively, and were cultured in the corresponding medium 
(100 μl/well) supplemented with 1% DMSO with or without specific amount of a test compound. After 4 
days of culture, cells were treated with CellTiter-Glo Reagent for measurement of luminescence, as a 
readout of ATP amount, according to the manufacturer’s instruction (Promega), using Gene Light 55 
Luminometer (Microtech, Chiba, Japan). Cell seeding density was optimized through a series of pilot 
experiments, to confirm that cell numbers at the end of four days of culture were proportionate to 
intensities of luminescence. Relative cell number was calculated based on ratio of the luminescence 
intensity in compound-treated cells to that in non-treated cells of the same set of experiments. For each 
compound exposure, three sets of experiments were conducted as biological replicates. 
3.2.5 STATISTICAL ANALYSES 
Experiments to assess morphological impacts of compound exposures on EB morphology were 
conducted in three biological replicates using different collections of cell suspensions. For each replicate, 
16 hanging drops were generated per exposure (a specific concentration of compound) in parallel with 16 
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control (i.e., no compound) hanging drops (Fig. 3.1). Area and EDI of individual Day 4 EBs were 
normalized against the average of control EBs, and defined as relative area and relative EDI, 
respectively, expressed in percentages (i.e., averages of relative area and relative EDI of control EBs are 
100%). Data from 3 replicates were compiled, and their averages are shown with 95% confidence 
intervals (Fig. 3.2). Thus, a total of 46 to 48 EBs were scored for each exposure (1 or 2 EBs were 
occasionally lost or damaged during operations). To verify that observed effects on EBs were statistically 
significant, two-sample t-test was performed between compound-treated group and the matching control 
group. All morphological impacts that were defined as adverse in the present study were statistically 
significant (P < 0.01). 
43 
 
3.3 - Results 
3.3.1 EXPERIMENTAL DESIGN 
The overall experimental scheme is shown in Fig. 3.1. In the present study, we examined several 
concentrations for each compound in addition to those in the Daston list (Daston et al., 2014). 
Particularly, when Daston’s positive exposures had no apparent effect on P19C5 EBs, higher 
concentrations were also evaluated. EBs were observed daily for survival and integrity. On the fourth day 
of culture (Day 4), EBs were photographed and analyzed using the ImageJ program to measure the 
morphometric parameters, namely area and EDI (see Materials and Methods). Impact of each compound 
exposure was assessed based on changes in area or EDI relative to control EBs. In the present study, a 
compound exposure was classified as having an “adverse” effect on EB morphogenesis when it caused 
either of the following three outcomes: (1) degeneration (i.e., death) of EBs at any time point in culture or 
cell aggregation failure, (2) a reduction in the average area by more than 20% relative to control EBs, and 
(3) a decrease or increase in the average EDI by more than 40% relative to control EBs. Note that an 
increase in the average EDI accompanied by an increase in the average area was not classified as 
“adverse”, because such condition suggests “promotion” of EB growth and morphogenesis rather than 
“impairment” (see Discussion).  
3.3.2 EFFECTS OF THE POSITIVE AND NEGATIVE EXPOSURES ON EB MORPHOGENESIS 
Morphogenetic impacts of compound exposures on P19C5 EBs are shown in Fig. 3.2 and 
summarized in Tables 2 and 3 with respect to specific concentrations indicated in the Daston list. Sample 
images of EBs, namely those that were distinctly affected by exposures, are shown in Fig. 3.3. Based on 
the classification criteria described above, 58.8% (10 out of 17) of the positive exposures tested had 
adverse impact on P19C5 EBs (Table 2.2). Specifically, acetazolamide (120 μM) reduced relative area by 
25% and reduced relative EDI by 45%; all-trans retinoic acid (ATRA; 200 nM) reduced relative area by 
60% and reduced relative EDI by 90%; caffeine (325 μM) increased relative EDI by 70%; hydroxyurea 
(350 μM) caused death; mono(2-ethylhexyl) phthalate (MEHP; 150 μM) reduced relative area by 25%; 
methoxyacetate (5 mM) reduced relative area by 25% and reduced relative EDI by 90%; methylmercury 
(5 μM) caused death; nilotinib (28 μM) prevented cell aggregation (without apparent cell death); 
ramelteon (80 μM) increased relative EDI by 45%; and salicylic acid (3 mM) reduced relative area by 
60%. In contrast, only 17.6% (3 out of 17) of the negative exposures exhibited adverse effects on EB 
development (Table 3.3). Namely, butylparaben (110 μM) reduced relative area by 55%; nilotinib (2 μM) 
reduced relative area by 25%; and propylene glycol (850 mM) caused death. Overall, a significantly 
higher percentage of the positive exposures exhibited adverse impacts on EBs than the negative 
exposures (P = 0.013; chi-square test). 
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No adverse effect was observed in the P19C5 gastrulation model in response to seven of the 
Daston’s positive exposures, namely abacavir (80 μM), artesunate (20 nM), dabigatran (7 μM), ethylene 
glycol (57 mM), fingolimod (67 nM), glycolic acid (5 mM), and methanol (270 mM). Thus, we further 
examined whether EBs could be affected by these compounds at higher concentrations than those 
indicated in the Daston list. Artesunate, fingolimod, or methanol did not show any adverse effect on EB 
morphogenesis even at four times higher concentrations (Fig. 3.2), suggesting that the P19C5 
gastrulation model is unable to detect developmental toxicity of these compounds at physiologically 
relevant concentrations. However, abacavir at four times higher concentration (320 μM) reduced relative 
area by 25%; dabigatran at two times higher concentration (14 μM) reduced relative area by 21%; 
ethylene glycol at four times higher concentration (228 mM) reduced relative area by 25%; and glycolic 
acid at four times higher concentration (20 mM) reduced relative area by 80% and reduced EDI by 70%. 
This suggests that the P19C5 gastrulation model may still be able to detect these four developmental 
toxicants, albeit with slightly less sensitivity than in vivo. 
Ten of the Daston compounds evaluated (abacavir, ATRA, caffeine, dabigatran, ethylene glycol, 
glycolic acid, MEHP, methanol, nilotinib, and ramelteon) are categorized as both positive and negative 
exposures depending on concentrations. Such compounds are the most useful to rigorously validate the 
sensitivity and specificity of screening assays (Daston et al., 2014). Accordingly, to the classification 
criteria described above, the P19C5 EB model was able to distinguish between positive and negative 
exposures for four of these compounds (ATRA, caffeine, MEHP, and ramelteon). If four times higher 
concentrations were also to be included for positive exposures, additional four compounds (abacavir, 
dabigatran, ethylene glycol, and glycolic acid) can also be differentially classified by the P19C5 EB model. 
3.3.3 CYTOTOXICITY ON SOMATIC CELL LINES 
Three of the negative exposures adversely impacted the P19C5 gastrulation model. Namely, 
butylparaben and nilotinib reduced EB size, whereas propylene glycol caused death of EBs. Thus, these 
negative exposures appeared to be detrimental to growth or survival of P19C5 EBs, raising the possibility 
that the gastrulation model may be overly sensitive to these compound exposures, leading to 
misclassifications. To test whether harmful effects of these exposures are unique to the P19C5 EBs, we 
performed cell viability assay using monolayer cultures of P19C5 cells as well as three types of somatic 
cell lines, NIH/3T3 (mouse embryonic fibroblast-derived), HEK293 (human embryonic kidney-derived), 
JEG3 (human trophoblast-derived). These cell lines were cultured for four days in the presence of 
butylparaben, nilotinib, or propylene glycol, and impact on cell proliferation or survival was scored. All cell 
lines were completely killed by propylene glycol at the negative exposure concentration (850 mM) (Fig. 
3.4). Butylparaben at the negative exposure concentration (110 μM) also consistently reduced relative cell 
numbers of all four cell lines (Fig. 3.4). Thus, these two negative exposures appeared to exhibit cytotoxic 
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effects on not only P19C5 cells but also on other cell lines. On the other hand, relative cell numbers were 
not consistently reduced by nilotinib in any of the cell lines at the negative exposure concentration (2 μM) 
(Fig. 3.4). 
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3.4 - Discussion 
The present study evaluated our in vitro gastrulation model of P19C5 stem cells in reference to 
the Daston list of compound exposures for developmental toxicity assays. Based on the morphogenetic 
effects on EBs, 10 out of 17 positive exposures were classified as adverse, whereas 14 out of 17 
negative exposures were non-adverse. As shown in the previous study, valproic acid at 0.8 mM, another 
positive exposure in the Daston list, also causes adverse effect on P19C5 EB morphogenesis (Li and 
Marikawa, 2016). Thus, altogether, 25 out of 35 exposures in the Daston list (71.4%) were correctly 
classified by morphology-based assay using the P19C5 gastrulation model. When up to four times higher 
concentrations are included in assessment of the positive exposures, additional four exposures were also 
classified correctly, totaling 29 out of 35 (82.9%), although the validity of such an ad hoc criterion will 
require additional biological and toxicological justification. 
To date, various types of non-animal alternatives have been explored as developmental toxicity 
screening assays, including those utilizing differentiation, migration, or metabolomics of mouse or human 
ES cells (Kuske et al., 2012; Palmer et al., 2013; Seiler and Spielmann, 2011; Theunissen et al., 2012; 
Xing et al., 2015), rodent whole embryo culture (Piersma et al., 2004), micromass culture of limb bud 
mesenchyme (Pratten et al., 2012), and non-mammalian model systems, namely zebrafish embryos 
(Sipes et al., 2011). At present, it may not be fruitful to discuss effectiveness of the P19C5 gastrulation 
model in comparison with these assays, because no validation study has been reported in reference to 
the Daston list, to the best of our knowledge. Evaluations of other non-animal alternatives using the 
Daston list should provide solid framework for direct comparisons between different assays to reveal their 
strengths and weaknesses and help to assemble a proper battery of tests to screen a broad range of 
developmental toxicants. 
In the present study, the effects of compound exposures on the P19C5 gastrulation model were 
evaluated solely based on the morphological features, namely the size and shape of EBs. However, the 
effects of compounds may also be evaluated through gene expression analyses, because P19C5 EBs 
exhibit distinct temporal and spatial gene expression patterns that are characteristic of early 
embryogenesis during axial elongation and patterning (Lau and Marikawa, 2014; Li and Marikawa, 2015; 
Marikawa et al., 2009). Effects on gene expression are generally considered to be more sensitive 
endpoints when assessing developmental toxicity, and various types of gene expression analyses have 
been incorporated into stem cell-based in vitro assays, particularly ESTs, to augment their detection of 
developmental toxicants (Buesen et al., 2009; Gao et al., 2014; Panzica-Kelly et al., 2013; Pennings et 
al., 2011; Suzuki et al., 2011; zur Nieden et al., 2001). This notion applies to the response of P19C5 EBs 
to DAPT, a pharmacological inhibitor of Notch signaling, which markedly down-regulates expression of 
somitogenesis regulator genes, such as Hes7, Lfng, and Nrarp, without significantly altering EB size or 
shape (Li and Marikawa, 2015). However, the use of gene expression analyses to detect developmental 
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toxicants requires cautious interpretation, as the heightened sensitivity may increase the rate of false 
positive results. Mouse genetic studies, using the targeted gene knockout technology, have demonstrated 
in various cases that the loss of important developmental regulator genes fails to cause overt phenotypic 
abnormalities, due to existence of compensatory or redundant mechanisms (Barbaric et al., 2007; Nowak 
et al., 1997). Thus, alterations in gene expression may not correlate with the dramatic phenotypic effects 
(e.g., embryonic death or major fetal malformations) referenced in the Daston list. 
Among the 34 exposures from the Daston list examined here, the negative exposure of ATRA 
(1.7 nM) was particularly unique in that it markedly increased relative area of EBs. Because relative EDI 
was concomitantly increased, ATRA at the low concentration appeared to promote growth and axial 
elongation of EBs. Although ATRA is teratogenic at excessively high concentrations, it also acts at low 
physiological concentrations as an endogenous regulator of cell proliferation and embryo body patterning 
(Clagett-Dame and Knutson, 2011). Inactivation of Aldh1a2 gene, which encodes retinaldehyde 
dehydrogenase to synthesize ATRA, impairs growth and axial elongation in mouse embryos 
(Niederreither et al., 1999). Likewise, treatment of P19C5 EBs with BMS493, a pharmacological 
antagonist of retinoic acid receptors, reduces relative area and EDI, suggesting that active retinoic acid 
signaling is essential for growth and axial elongation in the in vitro gastrulation model (Li and Marikawa, 
2015). The source of retinoic acid or its precursors in the culture medium used in the present study was 
possibly bovine serum (Materials and Methods), and it may not have contained sufficient amount to 
support maximal growth and axial elongation of EBs. Thus, supplementation of a small amount of ATRA 
(as in the case for 1.7 nM exposure) would be beneficial for more robust EB development in vitro. 
Artesunate, fingolimod and methanol caused no adverse effect on the P19C5 gastrulation model 
even at four times higher concentrations than those indicated as positive exposures in the Daston list. 
These “false negative” misclassifications may exemplify some of the limitations and weaknesses of the 
model. Artesunate, an anti-malaria medication, is rapidly converted to its active metabolite 
dihydroartemisinin, which exerts developmental toxicity by generating free radicals that damage 
embryonic erythroblasts (Clark et al., 2008; Li et al., 2009). Depletion of primitive embryonic erythroblasts 
likely accounts for the observed cardiovascular and skeletal abnormalities caused by artesunate 
treatment (Clark, 2009; White et al., 2006; Clark et al., 2008; White and Clark, 2008). The developmental 
toxicity of fingolimod, an immunomodulator, also manifests as abnormal vascular maturation and cardiac 
malformation, mediated by inhibition of the sphingosine-1 phosphate receptor (FDA, 2010; Schmid et al., 
2007). The P19C5 gastrulation model may not accurately identify such developmental toxicants that 
selectively disrupt hematologic processes, because in vitro development of EBs does not require a 
vascular system. On the other hand, the developmental toxicity of methanol may be mediated by its 
metabolic byproduct, formate (Andrews et al., 1995). Compounds that become teratogenic only after 
chemical modifications by maternal metabolism are termed, “proteratogens” (Wells and Winn, 1996). 
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Detection of proteratogens is often considered a weakness of in vitro screens for developmental 
toxicants, because these assays usually lack the maternal metabolic system. Future studies will address 
whether the P19C5 model is susceptible to formate, and explore the incorporation of an exogenous 
metabolic activation system, such as co-culture with hepatocytes (Hettwer et al., 2010; Oglesby et al., 
1986) or liver microsome fractions (Luijten et al., 2008; Zhao et al., 1993). 
Practically speaking, misclassification of negative exposures (i.e., false positives) may be more 
detrimental for effectiveness of developmental toxicity assays, as compared to misclassification of 
positive exposures (i.e., false negatives). Unnecessary dismissal of safe compound exposures based on 
incorrect assay outcomes is disadvantageous for pharmaceutical development and burdensome for 
regulatory agencies (Waring et al., 2015). In the case of the P19C5 gastrulation model, three negative 
exposures gave false positive outcomes: butylparaben at 110 μM (reduction in area by 55%), nilotinib at 2 
μM (reduction in area by 25% and increase in EDI by 60%), and propylene glycol at 850 mM (death). The 
butylparaben and propylene glycol exposures diminished proliferation or survival of three somatic cell 
lines. Such general cytotoxicity may lead to misclassification of these exposures by other in vitro assays 
as well. It is unclear how such cytotoxic exposures are apparently harmless to developing embryos in vivo 
(Daston et al., 2014). It is important to note that the compound concentrations indicated in the Daston list 
are Cmax, and therefore developing embryos may not be exposed to such concentrations in a continuous 
manner, especially when compound clearance by the mother is rapid. Indeed, both butylparaben and 
propylene glycol have elimination half-lives of approximately four hours and undergo biotransformations 
in vivo (Aubert et al., 2012; Morshed et al., 1988). Additional pharmacokinetics information, namely area 
under the curve (AUC), may be more applicable to in vitro experimental conditions, and may help resolve 
this potential discrepancy. In contrast, the nilotinib negative exposure did not consistently diminish 
proliferation of the somatic cell lines, suggesting that adverse effect was specific to the P19C5 
gastrulation model. Interestingly, nilotinib at the high concentration (28 μM; positive exposure in the 
Daston list), exhibited an unusual impact, i.e., P19C5 cells in hanging drops failed to aggregate while they 
were still alive and proliferating. Although spontaneous cell aggregation is an essential step in generating 
EBs, this process does not correspond to normal embryonic development. Thus, nilotinib may be altering 
cellular properties that are not embryologically relevant, and such non-physiological effects of nilotinib, 
even at lower concentrations, may have contributed to false positive misclassification of the compound 
exposure. 
 In the future, the exposure-based validation list (Daston et al., 2014) will likely be expanded and 
refined as additional in vivo data on developmental toxicity and pharmacokinetics become available for 
various compounds. As previously suggested (Wise, 2016), it may be important to categorize positive 
exposures into distinct groups according to severity and nature of developmental toxicity. For example, 
the mechanism of an exposure that results in embryonic death is fundamentally different from an 
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exposure that causes spina bifida or microcephaly. Should such differences in in vivo impact be reflected 
in the outcomes of in vitro assays? In the present study, the P19C5 gastrulation model exhibited various 
responses to the positive exposures, ranging from total degeneration to a reduction in axial elongation. 
The range of phenotypic responses warrants further investigations to examine whether these variations in 
EB integrity and morphology correlate with the nature and severity of in vivo effects observed after 
exposure to the corresponding developmental toxicants. 
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Figure 3.1. The experimental scheme to examine morphogenetic impact of the compound exposures. 
See Materials and Methods for details.  
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Figure 3.2. Impact of the Daston compounds on P19C5 EB morphogenesis. For each compound, 
concentrations tested are indicated in the top row of the table with a summary of observed morphogenetic 
impact on EB area and EDI, indicated with upward arrowheads (increase) and downward arrowheads 
(reduction). No area or EDI value is available when EBs were dead (D) or cells did not aggregate (NA). 
Arrows above the table indicate negative (white arrow) and positive (black arrow) exposures as cited in 
the Daston list. Column graphs below the summary tables show averages of relative area (white columns) 
and relative EDI (gray columns), for the corresponding compound concentrations indicated above. Error 
bars show 95% confidence intervals. Asterisks indicate adverse impacts, which are defined in the present 
study as a change in average area by >20% or a change in average EDI by >40% relative to controls. 
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Figure 3.2. (Continued). Impact of the Daston compounds on P19C5 EB morphogenesis. For each 
compound, concentrations tested are indicated in the top row of the table with a summary of observed 
morphogenetic impact on EB area and EDI, indicated with upward arrowheads (increase) and downward 
arrowheads (reduction). No area or EDI value is available when EBs were dead (D) or cells did not 
aggregate (NA). Arrows above the table indicate negative (white arrow) and positive (black arrow) 
exposures as cited in the Daston list. Column graphs below the summary tables show averages of 
relative area (white columns) and relative EDI (gray columns), for the corresponding compound 
concentrations indicated above. Error bars show 95% confidence intervals. Asterisks indicate adverse 
impacts, which are defined in the present study as a change in average area by >20% or a change in 
average EDI by >40% relative to controls. 
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Figure 3.3. Representative images of P19C5 EBs. Not all compound exposures are shown (see text). 
Each set of images shows a control group of EBs (no test compound) and one or two compound-treated 
groups of EBs, made from the same cell suspension as the control. Scale bars = 500 μm. 
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Figure 3.4. Relative cell numbers of four cell lines, P19C5, NIH/3T3, HEK293 and JEG3, that are cultured 
as monolayer in the presence of butylparaben, nilotinib, or propylene glycol, at the negative exposure 
concentration indicated in the Daston list. Data points for three biological replicates are shown using 
different marker styles. 
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Figure 3.5. Extended ranges of treatment concentrations to identify the LOAELs of selected chemical 
exposures in the Daston list. Initial treatment ranges included the concentrations listed by Daston et al. 
and included 2- and 4-fold increases or decreases (Fig. 3.2). If the chemical showed no significant effects 
at the initial concentrations tested, then the range was increased to the LOAEL or the maximum possible 
treatment (e.g., artesunate, fingolimod, methanol, saccharin and zaleplon). Chemicals that had effects at 
concentrations lower than specified in the Daston list (e.g., acetazolamide, butylparaben, methylmercury, 
nilotinib, propylene glycol and salicylic acid) were treated with additional lower dilutions until the NOAEL 
was reached.  
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Table 3.1. Compounds used in the Daston validation study. 
Compound 
 
Vendor Catalog Number Stock 
Abacavir Sigma-Aldrich SML0089 50 mM in water 
Acetazolamide Sigma-Aldrich A6011 50 mM in DMSO 
All-trans retinoic acid Sigma-Aldrich R2625 200 μM in DMSO 
Artesunate Sigma-Aldrich A3731 50 mM in DMSO 
Butylparaben Sigma-Aldrich PHR1022 50 mM in DMSO 
Caffeine Sigma-Aldrich C0750 1 M in water 
Dabigatran Santa Cruz Biotech. sc-351724 20 mM in DMSO 
Desloratadine Sigma-Aldrich D1069 1 mM in DMSO 
Ethylene glycol Sigma-Aldrich 324558 18 M (100%) 
Fingolimod Sigma-Aldrich SML0700 20 mM in water 
Glycolic acid Sigma-Aldrich G8284 1 M in water 
Hydroxyurea Sigma-Aldrich H8627 100 mM in water 
MEHP Santa Cruz Biotech. sc-396467 100 mM in DMSO 
Methanol Fisher Scientific A412P-4 24.7 M (100%) 
Methoxyacetate Sigma-Aldrich 194557 10 mM in water 
Methylmercury Sigma-Aldrich 442534 10 mM in DMSO 
Nilotinib Santa Cruz Biotech. sc-202245 50 mM in DMSO 
Oseltamivir Santa Cruz Biotech. sc-208135 50 mM in water 
Propylene glycol Sigma-Aldrich PHR1051 13.62 M (100%) 
Ramelteon Santa Cruz Biotech. sc-219934 20 mM in DMSO 
Saccharin Sigma-Aldrich 240931 20 mM in water 
Salicylic acid Sigma-Aldrich 247588 1 M in DMSO 
Zaleplon Sigma-Aldrich Z-004 3.28 mM in methanol 
Zidovudine Sigma-Aldrich PHR1292 100 mM in DMSO 
 
DMSO: Dimethylsulfoxide, MEHP: Mono(2-ethylhexyl) phthalate 
57 
 
Table 3.2. Adverse impacts of the Daston positive exposures on EB morphology. 
Compound Concentration Adverse impact Comments 
 
Abacavir 80 μM No Area reduction at 4× higher 
conc. (320 μM) 
Acetazolamide 121 μM Yes (120 μM) Area and EDI reduction 
 
ATRA 200 nM Yes Area and EDI reduction 
 
Artesunate 20 nM No  
 
Caffeine  325 μM Yes EDI increase 
 
Dabigatran 7 μM No Area reduction at 2× higher 
conc. (14 μM) 
Ethylene glycol 57 mM No Area reduction at 4× higher 
conc. (228 mM) 
Fingolimod 67 nM No  
 
Glycolic acid 5 mM No Area and EDI reduction at 
4× higher conc. (20 mM) 
Hydroxyurea 350 μM Yes Dead 
 
MEHP 146 μM Yes (150 μM) Area reduction 
 
Methanol 270 mM No  
 
Methoxyacetic acid 5 mM Yes Area and EDI reduction 
 
Methylmercury 5 μM Yes Dead 
 
Nilotinib 28 μM Yes No aggregation 
 
Ramelteon 81 μM Yes (80 μM) EDI increase 
 
Salicylic acid 3 mM Yes Area reduction 
 
 
ATRA: All-trans retinoic acid, MEHP: Mono(2-ethylhexyl) phthalate 
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Table 3.3. Adverse impacts of the Daston negative exposures on EB morphology. 
Compound Concentration Adverse impact Comments 
 
Abacavir 18 μM No (20 μM) 
 
 
ATRA 1.7 nM No EDI increase accompanied 
by area increase (see text) 
Butylparaben 110 μM Yes Area and EDI reduction 
 
Caffeine 7.7 μM No 
 
 
Dabigatran 1 μM No 
 
 
Desloratadine 1.5 μM No 
 
Concentration listed as 1.5 
mM in Daston et al. 2014. 
Ethylene glycol 1.4 mM No 
 
 
Glycolic acid 275 μM No 
 
 
Methanol 22 μM No 
 
 
MEHP 1 μM No 
 
 
Nilotinib 2 μM Yes Area reduction, EDI 
increase 
 
Oseltamivir 12 μM No 
 
 
Propylene glycol 850 mM Yes Dead 
 
Ramelteon 19 nM No 
 
 
Saccharin 24 μM No 
 
 
Zaleplon 12 μM No 
 
 
Zidovudine 227 μM No 
 
 
 
ATRA: All-trans retinoic acid, MEHP: Mono(2-ethylhexyl) phthalate 
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CHAPTER 4. FLUOXETINE INHIBITS CANONICAL WNT SIGNALING TO 
IMPAIR EMBRYOID BODY MORPHOGENESIS: POTENTIAL TERATOGENIC 
MECHANISMS OF A COMMONLY USED ANTIDEPRESSANT 
4.1 - Introduction 
Many chemical compounds have the potential to disrupt sensitive processes of embryonic 
development, resulting in miscarriage or birth defects. For this reason, pregnant women are advised to 
avoid using any unnecessary medications, supplements or recreational drugs. However, some women 
with pre-existing medical conditions, such as depression, must continue taking medications during their 
pregnancies to maintain maternal physical and mental well-being. Depression affects 8 to 16% of women 
of reproductive age in the United States (Farr et al., 2010; Ko et al., 2012; Willet et al., 2012). Because 
untreated depression during pregnancy is associated with a range of adverse pregnancy outcomes, such 
as miscarriage, preterm birth, and lower birth weights (Udechuku et al., 2010), antidepressants are often 
prescribed for use during pregnancy. Unfortunately, some epidemiologic studies have suggested a higher 
incidence of birth defects in children exposed to antidepressants during embryonic development. To 
minimize the risk of preventable birth defects in human pregnancies, it is important to know which 
antidepressants are most likely to be teratogenic and which are least likely to cause harm if used during 
pregnancy. This understanding can only be obtained through continued investigations on the 
developmental toxicity of antidepressants using retrospective human epidemiologic studies as well as 
more prospective and mechanistic analyses using animal and in vitro models. With such information, 
clinicians can differentiate various types of antidepressants based on their relative safety for use during 
pregnancy and prescribe the safest medications to the patients. 
Fluoxetine (a.k.a. Prozac) is one of the most commonly prescribed antidepressants of the 
selective serotonin reuptake inhibitor (SSRI) class. By inhibiting the serotonin transporter (SERT; 
encoded by the SLC6A4 gene), fluoxetine and other SSRIs increase the synaptic levels of serotonin (5-
hydroxytryptamine or 5-HT), a monoamine neurotransmitter that helps to regulate mood. Several human 
epidemiologic studies have identified significant associations between maternal use of fluoxetine during 
pregnancy and an increased incidence of specific congenital anomalies, such as cardiac defects, 
pulmonary hypertension, gastroschisis and omphalocele (Ellfolk and Malm, 2010; Reefhuis et al., 2015; 
Wemakor et al., 2015)). The mechanism linking fluoxetine to these birth defects is unclear, but there are 
three primary possibilities: fluoxetine may inhibit SERT in the fetus, inhibit SERT in the mother, or affect 
an off-target molecule unrelated to serotonin signaling altogether. In the mouse embryo, SERT is 
expressed in the heart and liver as early as the E10.5 stage (Narboux-Nême et al., 2008). Fluoxetine may 
inhibit SERT in these embryonic tissues to directly cause organ malformations. Alternatively, the 
developmental toxicity of fluoxetine may be indirect if it acts on SERT in the pregnant mother, altering 
maternal physiology (i.e., decreasing placental blood flow) and resulting in adverse effects on embryonic 
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development. For example, fluoxetine causes severe anorexia in rats, leading to maternal starvation with 
secondary adverse reproductive outcomes (Sloot et al., 2009; Wong et al., 1988). Finally, fluoxetine may 
target non-SERT molecules that play essential roles in embryogenesis. In vivo studies with humans or 
model animals are often too complex to distinguish which of these possibilities is responsible for the 
teratogenic action of fluoxetine. On the other hand, in vitro tests are devoid of maternal factors and are 
more amenable to experimental manipulations and molecular analyses. Thus, in vitro models may 
provide valuable mechanistic insight into the developmental toxicity of fluoxetine. 
One such in vitro model uses stem cell-derived embryoid bodies capable of spontaneous axial 
morphogenesis to study the effects of developmental toxicants. These EBs are created from P19C5 
mouse stem cells, which possess developmental properties similar to the epiblast, the pluripotent 
embryonic precursor of the fetal body (Lau and Marikawa, 2014). P19C5 cells can be aggregated in a 
hanging drop of culture medium to differentiate as an embryoid body (EB), which transforms from a 
spherical mass to an elongated structure during four days of culture. This morphological transformation is 
an in vitro recreation of gastrulation, the morphogenetic process of body patterning and elongation along 
the cranial-caudal embryonic axis. The developmental toxicity of chemical agents can be assessed based 
on their adverse impact on the in vitro morphogenesis of P19C5 EBs, a model that was recently validated 
using the Daston list of reference chemical exposures (Daston et al., 2014; Warkus and Marikawa, 2017). 
The Daston list consists of 39 exposures, i.e., in vivo concentrations of specific compounds that cause 
adverse effects on embryos or lack thereof (Daston et al., 2014). Growth and morphogenesis of P19C5 
EBs were significantly altered by the adverse exposures in the Daston list, but not by the non-adverse 
exposures, with a total concordance of 71.4 to 82.9% (Warkus and Marikawa, 2017). Thus, the 
morphogenesis-based P19C5 EB assay can serve as an effective in vitro alternative to evaluate 
developmental toxicity of compounds at physiologically-relevant concentrations. 
The P19C5 EB morphogenesis model is also a useful tool to identify the molecular mechanisms 
of developmental toxicity. During the four days of culture, EBs exhibit dynamic gene expression patterns 
in a distinct temporal pattern that is similar to the time course of gene regulation in the in vivo embryo. For 
example, pluripotency maintenance genes (e.g., Pou5f1 and Nanog) are down-regulated by Day 1 of EB 
culture, whereas genes associated with the initial step of gastrulation (e.g., Brachyury, Mixl1, and Cdx1) 
show a strong peak expression on Day 1. In contrast, the genes involved in caudal development and 
somite formation have peak expression levels on Day 2 (e.g., Wnt3a, Tbx6, Notch1, and Hes7) or Day 3 
(e.g., Meox1 and Mesp2) (Lau and Marikawa, 2014; Li and Marikawa, 2015, 2016) (Table 4.1). The 
intensity and temporal patterns of these gene expressions are regulated by specific molecular signals, 
namely Wnt, Nodal, Fgf, Bmp, Notch, and retinoic acid, which was demonstrated using pharmacological 
inhibitors against each of these signaling pathways (Li and Marikawa, 2015). Disruption of a particular 
signal in EBs by the inhibitor causes distinct alterations in the gene expression patterns, yielding 
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“disruption profiles” that are specific to each signaling pathway. Comparison of these disruption profiles to 
the gene expression patterns of EBs exposed to a teratogen can provide mechanistic insight to identify 
which molecular signals are impacted by the teratogenic exposure. This strategy was demonstrated to be 
effective in a recent study, which revealed that valproic acid (a well-known teratogen) adversely affects 
morphogenesis by enhancing retinoic acid signaling (Li and Marikawa, 2016). 
In the present study, we used the P19C5 EB system to investigate the mechanism of fluoxetine’s 
effects on embryonic morphogenesis, particularly concerning its adverse concentration levels, impact on 
gene expression profiles, and molecular pathways that are independent of SERT inhibition. 
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4.2 - Materials and methods 
4.2.1 COMPOUNDS 
All chemical compounds used in the present study were commercially obtained, and their details 
are described in Table 2. 
4.2.2 CELL CULTURE AND EMBRYOID BODY GENERATION 
P19C5 cells were cultured and induced for in vitro morphogenesis, according to the methods 
described previously (Lau and Marikawa, 2014; Warkus and Marikawa, 2017). Briefly, cells were 
maintained in the P19 culture medium (Minimum Essential Medium Alpha, nucleosides, GlutaMAX 
Supplement [LifeTechnologies, Carlsbad, California], 2.5% fetal bovine serum, 7.5% newborn calf serum, 
50 units/mL penicillin and 50 μg/mL streptomycin). For embryoid body (EB) generation, cells were 
dissociated with TrypLE Express (LifeTechnologies) and suspended at a density of 10 cells/µL in the 
culture medium containing a final concentration of 1% (v/v) dimethyl sulfoxide (DMSO) with or without a 
test compound. Droplets (20 µL each) of cell suspension were deposited on the inner surface of Petri dish 
lids and were cultured for up to 4 days in an incubator with 4.5% CO2 at 37°C in humidified air. EBs were 
monitored daily for survival and overall integrity before being harvested for morphometric and gene 
expression analyses (Fig. 4.1). 
4.2.3 MORPHOMETRIC ANALYSES 
Images of EBs were obtained after 4 days of hanging drop culture (Day 4) and opened in the 
ImageJ program (http://rsb.info.nih.gov/ij) for morphometric analyses, as previously described (Warkus 
and Marikawa, 2017). Briefly, the outline (perimeter) of individual EBs was automatically identified using a 
macro and measured to obtain morphometric parameters, such as area and circularity (Fig. 4.10). Area 
was used to estimate the overall size of EBs, whereas the elongation distortion index (EDI), which is 
calculated from circularity (EDI = 1/circularity - 1), was used to assess the extent of EB axial elongation. 
Area and EDI were normalized by the average values of control EBs in each set of experiments, and 
were reported as relative area and relative EDI, respectively, expressed in percentages (the average 
values of control are 100%). Three sets of experiments were conducted for each treatment condition as 
biological replicates, and relative area and relative EDI were compiled and presented as mean ± 95% 
confidence intervals. Adverse morphogenetic effects were defined as a reduction in relative area by >20% 
and/or a change in relative EDI by >40%, which are thresholds based on the criteria established in the 
previous validation study (Warkus and Marikawa, 2017). 
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4.2.4 REVERSE TRANSCRIPTION AND POLYMERASE CHAIN REACTION (RT-PCR) ASSAYS 
Total RNA was extracted from cell suspension prior to aggregation (Day 0) and from EBs on 
Days 1, 2, 3, and 4, using TRI reagent (LifeTechnologies) and Direct-zol RNA MiniPrep kit (Zymo 
Research, Irvine, CA), and processed for cDNA synthesis using M-MLV Reverse Transcriptase 
(Promega, Madison, WI) and oligo-dT (18) primer. The preparation of cDNA from the mouse whole 
embryo was described previously (Li and Marikawa, 2015). Standard RT-PCR was used to detect mRNAs 
of Slc6a4 (encoding the serotonin transporter) and Slc6a2 (encoding the norepinephrine transporter), 
using JumpStart REDTaq DNA Polymerase (Sigma-Aldrich) with the following conditions: initial 
denaturation at 94°C for 5 min; 35 cycles of 94°C for 15 sec, 60°C for 20 sec, and 72°C for 40 sec; and a 
final extension at 72°C for 5 min. Amplified products were resolved in a 1% agarose gel and visualized by 
staining with ethidium bromide. Note that primers for Slc6a4 (F: 5’-GTT CTG CAG CGA CGT GAA GGA 
AAT-3’, R: 5’- GCT TAG AGG GGA GGA GTC AAG GTG-3’) and Slc6a2 (F: 5’- GTG GTG GTC AGC 
ATC ATC AAC TTC-3’, R: 5’- AAC CAG CGT CAC GGA ATC ATT AGT-3’) were designed as intron-
spanning, so that PCR products amplified from cDNA could be distinguished from those from genomic 
DNA based on the product size (416 and 420 bp for Slc6a4 and Slc6a2 mRNA, respectively). 
Quantitative RT-PCR was performed using the CFX96 Real-Time PCR Detection System (Bio-
Rad, Hercules, CA) with SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) as follows: initial 
denaturation at 94°C for 5 min, followed by up to 45 cycles of 94°C for 15 sec, 60°C for 20 sec, and 72°C 
for 40 sec. Data files were opened in CFX Manager software (Bio-Rad) and Ct values were transferred to 
the Excel program for further analyses. Actb, which encodes ß-Actin, was used as a constitutively-
expressed housekeeping gene to standardize the expression levels of the other genes. Relative 
expression level was calculated as a percentage relative to the total expression level of control EBs (a 
sum of Days 0, 1, 2, 3 and 4 values) in each set of experiments. Three sets of experiments were 
conducted for each treatment condition as biological replicates, and relative expression levels were 
compiled and presented as mean ± standard deviation. 
4.2.5 LUCIFERASE REPORTER ASSAYS 
The plasmids used for luciferase reporter assays were obtained commercially or from other 
researchers. TOPFLASH (Upstate, Charlottesville, VA) consists of the firefly luciferase gene controlled by 
the transcriptional promoter containing multiple TCF-binding sites and serves as a reporter for active 
canonical Wnt signaling. FOPFLASH (Upstate), used as a negative control for TOPFLASH, contains 
inactivating mutations in the TCF-binding sites. pRL-TK (Promega) encodes the Renilla luciferase gene 
under the control of a constitutive promoter (thymidine kinase promoter) and was used to normalize the 
luciferase activities of TOPFLASH and FOPFLASH. L1CBD-G4DBD encodes a chimeric protein 
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containing the ß-Catenin-binding domain of LEF1 and the DNA-binding domain of GAL4. Like 
TOPFLASH, L1CBD-G4BD serves as a monitoring tool for active canonical Wnt signaling, as previously 
described (Tamashiro et al., 2008). Binding of ß-Catenin to L1CBD-G4DBD forms a transcriptional 
activator to turn on the expression of the firefly luciferase from pG5-Luc, which contains multiple GAL4-
binding sites (Promega). G4DBD, which is GAL4-binding domain without a ß-Catenin domain, was used 
as a control for L1CBD-G4DBD (Tamashiro et al., 2008). ARE-Luc (a gift from Dr. Malcom Whitman; 
Harvard Medical School) consists of the firefly luciferase controlled by the activin response elements and 
serves as a reporter for active Nodal/Activin signaling (Weisberg et al., 1998). P19C5 cells in monolayer 
were transfected with the plasmids using Lipofectamine 2000 (LifeTechnologies). After 24 hours, cells 
were lysed and examined for luciferase activity using the Dual-Luciferase Reporter Assay System 
(Promega) with Gene Light 55 Luminometer (Microtech, Chiba, Japan). All experiments were repeated 
independently three times. The results are shown as mean ± standard deviation. 
4.2.6 CELL VIABILITY ASSAY 
Effect of chemical treatment on cell proliferation and viability was determined with the CellTiter-
Glo Luminescent Cell Viability Assay System (Promega), as described previously (Warkus et al., 2016). 
Briefly, P19C5 cells were seeded in 96-well plates at a density of 100 cells/well in 100 µL of culture 
medium supplemented with 1% DMSO containing the test compound or vehicle only as a control. After 4 
days of culture, cells were treated with CellTiter-Glo Reagent. The resulting luminescence was measured 
using Gene Light 55 Luminometer as a readout of ATP amount, which serves as a quantitative proxy for 
the number of metabolically active cells. The intensity of the luminescence was normalized to the control 
level (vehicle only) in each set of experiments and reported as relative light units. All experiments were 
repeated independently three times, and the results are shown as mean ± standard deviation.  
4.2.7 STATISTICS 
Statistical differences were assessed by two-sample t-test. For EB morphogenesis, relative area 
and relative EDI were compared between two groups of EBs, typically compound-treated EBs and 
vehicle-treated control EBs (n = 45–48 for each group, compiled from 3 sets of independent experiments), 
unless otherwise stated. Differences in average values were deemed significant when P values were < 
0.01. For luciferase reporter assays, normalized luciferase activities, i.e., ratios of the firefly luciferase to 
the Renilla luciferase signals, from three independent experiments were compared between compound-
treated and control (vehicle only) groups. For the cell viability assay, relative light units from three 
independent experiments were compared between compound-treated and control cells. 
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4.3 - Results 
4.3.1 FLUOXETINE IMPAIRS MORPHOGENESIS OF P19C5 EMBRYOID BODIES IN A DOSE-
DEPENDENT MANNER 
The teratogenic potential of fluoxetine was evaluated using the P19C5 embryoid body (EB) 
morphogenesis system (Fig. 4.1). P19C5 cells were aggregated in hanging drops of culture medium 
containing various concentrations of fluoxetine, and the morphology of the resulting EBs was examined 
after four days of culture. We focused on a concentration range between 2 and 10 µM, because our pilot 
study suggested that fluoxetine at 1 µM or less had no morphological impact whereas fluoxetine 
concentrations higher than 10 µM were detrimental to the survival of EBs. Treatment effects were 
quantified using two morphometric parameters, the two-dimensional area of EBs, which is a proxy for EB 
size, and the elongation distortion index (EDI), which was used to evaluate the extent of axial elongation. 
Following the previous validation study, morphologic impacts were only considered to be adverse if drug 
treatment caused a reduction in relative area by >20% or a reduction in relative EDI by >40% compared 
to control EBs (Warkus and Marikawa, 2017). EB morphogenesis was adversely affected by fluoxetine 
treatment at the exposures levels of 6 µM and higher, which reduced both relative area and relative EDI 
in a dose-dependent manner (Fig. 4.2A, B).  
We then evaluated the effects of R-fluoxetine, S-fluoxetine, and norfluoxetine on EB 
morphogenesis. Fluoxetine is a racemic mixture of R- and S-enantiomers. R-fluoxetine and S-fluoxetine 
are similar in their potency as serotonin reuptake inhibitors (SSRIs), although the latter (S) is slightly more 
potent than the former (R) (Wong et al., 1995). Norfluoxetine, the major metabolite of fluoxetine, is a 
potent SSRI with a longer half-life in the circulating plasma (Hiemke and Härtter, 2000). The 
morphogenetic effects of these compounds were tested at 2, 6, 10, and 20 μM, to match the experiments 
done with fluoxetine. All the compounds adversely affected EB morphogenesis at 6 μM and higher, 
although S-fluoxetine appeared slightly less potent than the others with respect to the extent of reduction 
in area and EDI (Fig. 4.2C, D). Thus, the morphogenesis of EBs was susceptible to exposures to 
fluoxetine, its enantiomers, and metabolite with largely similar dose-dependency. 
4.3.2 THE MORPHOGENETIC EFFECTS OF FLUOXETINE ARE NOT DUE TO INHIBITION OF THE 
SEROTONIN TRANSPORTER  
We assessed whether the action as an SSRI is responsible for the adverse morphogenetic 
effects of fluoxetine. First, expression of the Slc6a4 gene was examined in P19C5 EBs, as it encodes the 
serotonin transporter (SERT), the main target of SSRI action. For comparison, expression of the Slc4a2 
gene, which encodes the norepinephrine transporter (NET) was also examined, as both SERT and NET 
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are inhibited by antidepressants of the serotonin and norepinephrine reuptake inhibitor (SNRI) class, such 
as venlafaxine. Both Slc6a4 and Slc6a2 mRNAs were robustly expressed in the mouse embryo at the 
stage E10.5. Conversely, in P19C5 EBs (as a mixture of Days 0, 1, 2, 3, and 4), only Slc6a2 mRNA was 
robustly expressed (Fig. 4.3A). Quantitative RT-PCR analysis showed that Slc6a2 mRNA was highly 
expressed only at Day 0 (i.e., before cell aggregation), and that the expression of Slc6a4 mRNA was very 
low—less than 5% of the whole embryo level—at all stages of EBs (Fig. 4.3B). 
Although the level was very low, the expression of SERT may be sufficient to cause adverse 
effects in EBs if inhibited by fluoxetine. Thus, we evaluated the morphogenetic impact of other inhibitors 
of SERT, specifically citalopram (SSRI) and venlafaxine (SNRI). EB morphology was assessed after four 
days of treatment with either citalopram or venlafaxine at 0, 2, 6, 10 or 20 µM. Neither citalopram nor 
venlafaxine exhibited adverse effects even at the highest concentrations tested (Fig. 4.3C, D). Since 
SSRIs elevate the levels of extracellular 5-HT, we also tested the impact of excessive 5-HT on EB 
morphogenesis. None of the concentrations tested (ranging from 10 µM to 100 µM) caused adverse 
morphogenetic effects (Fig. 4.3E, F). These results indicate that the SSRI action is not responsible for the 
adverse morphogenetic effects of fluoxetine and suggest that fluoxetine may target molecular 
mechanisms unrelated to SERT when it interferes with embryonic morphogenesis. 
4.3.3 FLUOXETINE ALTERS EXPRESSION PATTERNS OF VARIOUS DEVELOPMENTAL REGULATOR 
GENES 
To gain mechanistic insight into the morphogenetic effects of fluoxetine, we examined how 
fluoxetine treatment alters expression patterns of key developmental regulator genes in EBs. EBs were 
treated with fluoxetine at the concentrations of 0 µM (control), 2 µM and 6 µM, and harvested at Days 0, 
1, 2, 3, and 4 for gene expression analyses by quantitative RT-PCR (Fig. 4.1). These concentrations were 
selected because 2 µM had no morphogenetic impact, whereas 6 µM was the lowest concentration that 
altered both area and EDI (Fig. 4.2B). The developmental regulators examined are transcription factors 
and signaling molecules that are crucial for embryo patterning and germ layer formation, and their 
characteristics are summarized in Table 1. 
Fluoxetine at 2 µM did not significantly alter the transcript levels of any of the developmental 
regulators during EB development (Fig. 4.4A). However, fluoxetine at 6 µM changed the expression 
patterns of a number of genes relative to the patterns in vehicle-treated controls. In control EBs, the levels 
of the pluripotency maintenance genes (i.e., Pou5f1 and Nanog) were markedly down-regulated by Day 
1, whereas the genes involved in the initial phase of gastrulation (i.e., Brachyury, Mixl1 and Cdx1) were 
strongly up-regulated, indicating a swift initiation of the differentiation program within one day of 
aggregation culture. In contrast, EBs treated with fluoxetine (6 µM) exhibited a delay in differentiation, 
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such that the pluripotency genes continued to be highly expressed at Day 1 and the up-regulation of the 
initial gastrulation genes was less robust than control (Fig. 4.4A). A delay in differentiation was also 
evident in the expression patterns of other genes, such as the regulators of caudal patterning and somite 
formation (i.e., Wnt3a, Tbx6, Hes7, and Meox1). In these genes, the up-regulation towards the peak 
expression (on Day 2 for Wnt3a, Tbx6, and Hes7, and on Day 3 for Meox1) was diminished in fluoxetine-
treated EBs compared to control EBs (Fig. 4.4A). This delayed differentiation seemed specific to the 
mesodermal lineage since genes expressed in the neural lineage (i.e., Sox2, Otx2, Hoxc6, and Pax3) 
were either elevated or largely unaffected by fluoxetine treatment (Fig. 4.4A). These results suggest that 
fluoxetine treatment (6 µM) is detrimental for mesodermal differentiation but is neutral or even permissive 
for neural differentiation in P19C5 EBs. 
Several major developmental signaling pathways, namely Wnt, Nodal, Fgf, Bmp, and retinoic acid 
(RA), regulate germ layer differentiation and body patterning during embryogenesis. These major 
pathways also control morphogenesis and gene expression in P19C5 EBs (Li and Marikawa, 2015). To 
assess whether fluoxetine alters these major developmental signals to cause adverse effects, we 
compared the gene expression profiles in fluoxetine-treated EBs with the “disruption profiles” of these 
signaling pathways. The previous study (Li and Marikawa, 2015) showed that the expression patterns of 
Pou5f1, Nanog, and Brachyury were differentially affected by inhibition of each of the major signaling 
pathways at Day 1 and Day 2, and, therefore, may be used to identify which pathway is disrupted (Fig. 
4.4B). The impact of fluoxetine (6 µM) was most similar to that of XAV939 (5 µM), an inhibitor of the 
canonical Wnt signaling pathway (Fig. 4.4B). However, two other signaling inhibitors (SB431542 [Nodal 
inhibitor] and PD173074 [Fgf inhibitor]) also caused a decrease in the Day 1 expression of the early 
mesoderm gene Brachyury, similarly to the impact of fluoxetine. To assess whether these three signaling 
pathways—Wnt, Nodal, and Fgf—are linked to the molecular impact of fluoxetine, we examined the target 
genes of these pathways: Sp5 for canonical Wnt signaling, Nodal for Nodal signaling, and Spry2 for Fgf 
signaling. Fluoxetine treatment caused a reduction in the expression of Sp5 at Day 1 but did not reduce 
Nodal or Spry2 expression (Fig. 4.4A), suggesting that fluoxetine at 6 µM may inhibit canonical Wnt 
signaling during EB development to alter EB morphogenesis.  
4.3.4 FLUOXETINE INHIBITS CANONICAL WNT SIGNALING IN P19C5 CELLS 
We tested whether fluoxetine inhibits canonical Wnt signaling using two luciferase reporter 
assays, both of which measure the transcriptional activation mediated by ß-Catenin (CTNNB1) as a 
readout of Wnt signaling activity (Fig. 4.5A). One assay employs TOPFLASH (Korinek et al., 1997), and 
the other utilizes L1CBD-G4DBD (Tamashiro et al., 2008). P19C5 cells in monolayer were transfected 
with the reporter constructs and treated with fluoxetine at various concentrations for 24 hours. The 
TOPFLASH signal was significantly reduced by fluoxetine at 6 µM or higher in a dose-dependent manner, 
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whereas the negative control FOPFLASH (containing mutations in the TCF-binding sites) yielded low 
signals regardless of fluoxetine concentration (Fig. 4.5B). Similarly, the L1CBD-G4DBD-dependent 
luciferase activity was significantly reduced by fluoxetine at 6 µM or higher (Fig. 4.5C). In contrast, the 
activity of ARE-Luc, a reporter construct for Nodal/Activin signaling (Weisberg et al., 1998), was not 
significantly reduced by fluoxetine or XAV939, whereas it was robustly repressed by SB431542 (Fig. 
4.5D). These results indicate that fluoxetine inhibits canonical Wnt signaling at the same concentrations 
that adversely affected EB morphogenesis. 
The impact of the fluoxetine enantiomers and the other SERT inhibitors was also assessed using 
the luciferase assays to further clarify the relationship between Wnt inhibition and morphogenetic effects. 
Both R-fluoxetine and S-fluoxetine reduced the TOPFLASH signal in a dose-dependent manner (Fig. 
4.5E). S-fluoxetine appeared to be slightly less potent than R-fluoxetine, which corresponded to the 
observed impact on EB morphogenesis (Fig. 4.2C). The TOPFLASH signal was not significantly reduced 
by citalopram, venlafaxine, or 5-HT at any of the concentrations tested (Fig. 4.5F), suggesting that 
inhibition of SERT does not diminish canonical Wnt signaling. Overall, the inhibitory impact of the 
chemical exposures on canonical Wnt signaling was consistent with their adverse effects on EB 
morphogenesis. 
4.3.5 ACTIVATION OF CANONICAL WNT SIGNALING PARTIALLY ALLEVIATES THE ADVERSE 
EFFECTS OF FLUOXETINE 
We then tested whether the adverse morphogenetic effects of fluoxetine can be rescued by 
forced activation of canonical Wnt signaling. CHIR99021 is a pharmacological inhibitor of GSK3 and is 
widely used to activate canonical Wnt signaling in various cell types (Fig. 4.5A). In P19C5 cells, 
CHIR99021 increased the TOPFLASH signal in a dose-dependent manner in the presence of fluoxetine 
at the adverse effect concentrations (6 and 10 µM), indicating that CHIR99021 can overcome fluoxetine 
to activate canonical Wnt signaling (Fig. 4.6A). However, high concentrations of CHIR99021 alone also 
adversely affected EB morphology. EBs treated with CHIR99021 at 1 µM or higher were rounder than 
control EBs, resulting in a significant reduction in EDI (Fig. 4.6B). This finding suggests that excessive 
and ubiquitous activation of canonical Wnt signaling is also detrimental to proper axial morphogenesis. 
Therefore, a rescue experiment for fluoxetine needs to be executed using concentrations of CHIR99021 
lower than 1 µM to avoid overactivation of Wnt signaling. 
EBs were treated with fluoxetine (6 µM) together with CHIR99021 at 0.1 or 0.3 µM, and EB 
morphology was assessed after four days of culture. Compared to fluoxetine alone, EBs treated with 
fluoxetine and CHIR99021 were more elongated (Fig. 4.6C). Both 0.1 and 0.3 µM of CHIR99021 were 
able to significantly increase the EDI of fluoxetine-treated EBs, but the 0.1 µM treatment appeared to be 
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more effective (Fig. 4.6D). Although the extent of rescue was partial, this result supports that the inhibition 
of canonical Wnt signaling is responsible for the adverse morphogenetic effects of fluoxetine. 
4.3.6 TRIFLUOROMETHYLPHENYL MOIETY OF FLUOXETINE IS ESSENTIAL IN CAUSING THE 
ADVERSE EFFECTS OF FLUOXETINE 
XAV939 is a pharmacological inhibitor of tankyrases (TNKS; (Huang et al., 2009), which are 
negative regulators of AXIN, the rate-limiting component of the ß-Catenin destruction complex (Fig. 4.5A). 
In examining the chemical structure of XAV939 and fluoxetine, we noticed that both molecules contain a 
trifluoromethylphenyl group (Fig. 4.7A, B). Norfluoxetine, which had similar morphologic effects to its 
parent molecule, fluoxetine (Fig. 4.2C), also contains a trifluoromethylphenyl group (Fig. 4.7A). Because 
of the structural similarity, it is possible that fluoxetine may act similarly to XAV939 to inhibit canonical 
Wnt signaling and alter EB morphogenesis. To assess whether the trifluoromethylphenyl moiety in 
fluoxetine was necessary in causing its adverse impacts, we examined the effect of nisoxetine, a 
norepinephrine reuptake inhibitor (NRI). Nisoxetine is structurally similar to fluoxetine, except that a 
trifluoromethyl group on the aromatic ring (in para position) is replaced with a methoxy group (in ortho 
position) (Fig. 4.7A, B). Nisoxetine did not adversely affect EB morphogenesis even at the highest 
concentration evaluated (20 µM; Fig. 4.7C). In addition, nisoxetine did not significantly inhibit canonical 
Wnt signaling, based on the TOPFLASH assay (Fig. 4.7D). These results suggest the 
trifluoromethylphenyl moiety in fluoxetine mediates its morphogenetic impact and its inhibitory effect on 
Wnt signaling. 
4.3.7 FLUOXETINE DIMINISHES CELL PROLIFERATION INDEPENDENTLY OF ITS INHIBITORY 
EFFECTS OF WNT SIGNALING OR SERT 
Despite the similarities in structure and inhibitory effect on canonical Wnt signaling, XAV939 and 
fluoxetine exhibit different impacts on EB morphogenesis. XAV939 (0.5 - 5 µM) causes a marked 
reduction in EDI without affecting area (Li and Marikawa, 2015), whereas fluoxetine (6 - 10 µM) lowered 
both area and EDI (Fig. 4.2A). A reduction in area indicates that fluoxetine diminishes cell proliferation or 
viability during EB development. To further assess the cytostatic impact of fluoxetine, P19C5 cells in 
monolayer were cultured for four days in the presence of fluoxetine at various concentrations, and the 
number of viable cells was measured. Compared to the control, fluoxetine caused a dose-dependent 
decrease in the number of viable cells at 6 µM and higher (Fig. 4.8A). Note that 6 µM of fluoxetine 
decreased the viable cell number by about 20%, which was comparable to the extent of reduction in EB 
area at the same concentration of fluoxetine (Fig. 4.2B). Fluoxetine treatment at higher than 10 µM, which 
was detrimental to the survival of EBs, decreased the viable cell number by >95% in monolayer culture. 
This suggests that cytostatic effects of fluoxetine reduce EB growth. 
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R-fluoxetine, S-fluoxetine, and norfluoxetine also decreased the number of viable cells in 
monolayer culture in a dose-response manner comparable to the effect of fluoxetine, although S-
fluoxetine again appeared slightly less potent (Fig. 4.8A). In contrast, the viable cell number was not 
markedly reduced by nisoxetine even at the highest concentration examined (20 µM; Fig. 4.8A), 
suggesting that the trifluoromethylphenyl moiety is essential for the cytostatic effect of fluoxetine. 
Importantly, XAV939 (up to 2.5 µM) did not reduce the number of viable cells, although it markedly 
suppressed the TOPFLASH signal (Fig. 4.8B). Therefore, neither the inhibition of canonical Wnt signaling 
nor the possession of a trifluoromethylphenyl group was sufficient to diminish cell proliferation. 
Lastly, to test whether the action as an SSRI is linked to the cytostatic effect, the viable cell 
number in monolayer culture was assessed after exposure to citalopram, venlafaxine, or 5-HT (Fig. 4.8C, 
D). None of these compounds significantly decreased the viable cell number, suggesting that inhibition of 
SERT is not responsible for the cytostatic effect of fluoxetine. 
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4.4 - Discussion 
In the present study, we used the P19C5 EB morphogenesis model to investigate the 
developmental toxicity of fluoxetine, a common SSRI antidepressant that is often prescribed to women of 
reproductive age. EB morphogenesis was adversely affected by fluoxetine and norfluoxetine at 6 µM and 
above. Comparison to other serotonin reuptake inhibitors suggested that the adverse morphogenetic 
effects of fluoxetine were not mediated by SERT inhibition. Gene expression analyses in EBs showed 
that various developmental regulators were affected by fluoxetine, particularly those involved in 
mesodermal differentiation, and implied inhibition of canonical Wnt signaling. Signaling reporter assays 
confirmed that fluoxetine inhibits canonical Wnt signaling. Fluoxetine also exhibited cytostatic effects on 
P19C5 cells independently of its inhibition of SERT and Wnt signaling. We propose that the adverse 
morphogenetic impacts of fluoxetine reflect its effects on canonical Wnt signaling and cell proliferation 
rather than its therapeutic effects as a serotonin reuptake inhibitor (Fig. 4.9). Considering the 
epidemiological findings linking maternal fluoxetine intake with an increased incidence of birth defects, the 
present study provides mechanistic insight for further investigations into the safety of antidepressant use 
during pregnancy. 
The findings of this study are only relevant if developing embryos in vivo are exposed to 
fluoxetine and norfluoxetine at the levels that cause adverse effects in EBs (i.e., 6 µM or higher). A large 
multicenter study has shown that the mean plasma concentrations (± standard deviation) of fluoxetine, 
norfluoxetine, and a sum of the two in depressed patients are 0.31 ± 0.16 µM, 0.41 ± 0.16 µM, and 0.73 ± 
0.26 µM, respectively (Amsterdam et al., 1997). Other studies involving depressed patients or healthy 
volunteers are also consistent with these plasma concentrations (Brunswick et al., 2002; Cheer and Goa, 
2001; Teter et al., 2005). As fluoxetine and norfluoxetine appear to cross the placental barrier readily, in 
utero concentrations may be comparable to the maternal plasma levels (Kim et al., 2004, 2006). If that is 
the case, exposure levels to developing embryos on average may be one order of magnitude lower than 
the concentrations that caused adverse morphogenetic effects in the present study. However, fluoxetine 
and norfluoxetine exhibit tissue-specific accumulation, and their levels in the brain have been measured 
at concentrations 10 - 20 times higher than the plasma levels (Bolo et al., 2000; Karson et al., 1993). 
Thus, it is important to determine whether similar accumulation occurs in the embryo or the reproductive 
tract. Furthermore, other conditions, such as hepatic impairment, intake of other medications that inhibit 
metabolizing enzymes, and accidental overdose, may significantly increase the plasma concentrations of 
fluoxetine and norfluoxetine (Cheer and Goa, 2001). Therefore, although the average fluoxetine 
concentration during pregnancy may be below the adverse effect levels, many factors may temporarily 
increase exposure levels in certain individuals and contribute to the higher incidence of congenital 
malformations. 
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Fluoxetine inhibited canonical Wnt signaling in P19C5 cells. Although the exact mechanism by 
which fluoxetine interferes with Wnt signaling is unclear, the structural similarity to XAV939 raises the 
possibility that fluoxetine may act as an inhibitor of TNKS (tankyrase) to stabilize AXIN (Fig. 4.5A). 
Inhibition of canonical Wnt signaling by fluoxetine was also reported in a recent study using chondrogenic 
cells, in which the TOPFLASH signal and Wnt-mediated osteoarthritis-related phenotypes are attenuated 
by fluoxetine treatment (Miyamoto et al., 2017). The concentrations of fluoxetine that inhibited Wnt 
signaling in these cells (e.g., ≥ 5 µM to reduce the TOPFLASH signal) are comparable to the fluoxetine 
exposures (≥ 6 µM) that diminished Wnt signaling activity and altered EB morphology in the present 
study. Miyamoto et al. (2017) also demonstrated enhanced binding of ß-Catenin (CTNNB1) to AXIN in 
cell lysate in the presence of fluoxetine, suggesting that fluoxetine may directly inhibit canonical Wnt 
signaling by stabilizing the association of ß-Catenin with the destruction complex. Conversely, another 
study using hippocampal neural precursor cells (NPC) has reported that fluoxetine activates, rather than 
inhibits, canonical Wnt signaling, as evidenced by increases in nuclear ß-Catenin amount and the 
TOPFLASH signal (Hui et al., 2015). Note, however, that the activation of canonical Wnt signaling in 
NPCs is induced by fluoxetine treatment at 1 µM, which is substantially lower than the levels that inhibited 
Wnt signaling in chondrogenic and P19C5 cells. Interestingly, the accumulation of nuclear ß-Catenin and 
Wnt-induced cell proliferation are attenuated in NPCs by co-treatment with WAY-100635, an antagonist of 
the 5-HT receptor, which implies that the activation of Wnt signaling is caused by the SSRI action of 
fluoxetine (Hui et al., 2015). Thus, the apparent contradiction on how fluoxetine modulates Wnt signaling 
might be explained by the ability of NPCs to respond to the elevated 5-HT level caused by inhibition of 
SERT, which appears to be absent in P19C5 cells. If fluoxetine can directly act on the signaling 
components, such as TNKS, AXIN and ß-Catenin, then higher concentrations of fluoxetine might inhibit 
canonical Wnt signaling in NPCs as well. 
Inhibition of canonical Wnt signaling may contribute to the etiology of birth defects associated with 
maternal fluoxetine intake, specifically cardiac malformations, such as ventricular septal defect (VSD), 
atrioventricular septal defect (AVSD), and right ventricular outflow tract obstruction (RVOTO) (Ellfolk and 
Malm, 2010; Gao et al., 2017; Kioussi et al., 2002; Reefhuis et al., 2015; Ruiz-Villalba et al., 2016; 
Grigoryan et al., 2008; Azhar and Ware, 2016). Genetic studies in mouse embryos have demonstrated 
that canonical Wnt signaling plays crucial roles in the development of the heart (Gessert and Kühl, 2010; 
Ruiz-Villalba et al., 2016; Grigoryan et al., 2008; Azhar and Ware, 2016). Functional ß-Catenin is required 
for the differentiation of cardiac progenitors (Lin et al., 2007), the growth and diversification of the second 
heart field precursors into right ventricular and interventricular myocardium (Ai et al., 2007; Kwon et al., 
2007; Klaus et al., 2007), the migration of cardiac neural crest (Kioussi et al., 2002), and the formation of 
the septum from the endocardial cushion (Liebner et al., 2004). Misregulation of these events during heart 
development may result in cardiac malformations, such as VSD, AVSD, and RVOTO (Lalani and 
Belmont, 2014). Note, however, that these genetic studies are mainly based on the loss of ß-Catenin in 
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specific embryonic tissues, which probably abolishes the activity of canonical Wnt signaling completely. In 
contrast, Wnt signaling inhibition by fluoxetine at 6-10 µM appeared to be more modest than the loss of ß-
Catenin, judging from the extent of the TOPFLASH signal reduction (Fig. 4.5B). Further investigations are 
warranted to understand how moderate inhibition of canonical Wnt signaling affects the developing heart. 
The reduction of EB growth caused by fluoxetine was likely due to its cytostatic activity 
independently of its inhibitory effects on SERT and canonical Wnt signaling. Fluoxetine diminishes cell 
proliferation and viability in a variety of cell types, including breast cancer cell lines (Bowie, 2015; Sun et 
al., 2015), ovarian cancer cell lines (Lee et al., 2010), neuroblastoma cell lines (Choi et al., 2017), 
pheochromocytoma cells (Han and Lee, 2009), hippocampal cells (Post et al., 2000; Schaz et al., 2011), 
and hypothalamic neuroprogenitor cells (Sousa-Ferreira et al., 2014), at concentrations that correspond 
to the adverse effect levels in P19C5 cells. The negative impact of fluoxetine on cellular proliferation 
and/or survival has been hypothesized to occur via a number of molecular pathways, including induction 
of endoplasmic reticulum (ER) stress, generation of reactive oxygen species (ROS), activation of NF-κB, 
increased influx of extracellular calcium, and phosphorylation of mitogen-activated kinases (MAPKs) (Lee 
et al., 2010; Post et al., 2000; Choi et al., 2017). The anti-proliferative effects of fluoxetine may not be 
mediated by inhibition of SERT in some cases. In the pheochromocytoma cell line, fluoxetine enhances 
the effect of a cytotoxic agent (1-methyl-4-phenylpyridinium), whereas another SERT inhibitor 
amitriptyline attenuates the cytotoxic effect (Han and Lee, 2009). In the human embryonic kidney cell line, 
the dose-response profiles of the anti-proliferative effects of fluoxetine are similar between unmanipulated 
cells (no SERT expression) and those with SERT overexpression (Schaz et al., 2011). The mechanism by 
which fluoxetine interacts with the molecular pathways described above in an SERT-independent manner 
is still unclear. Nonetheless, it is of interest to investigate the involvement of these pathways in the 
fluoxetine-induced reduction in P9C5 EB growth and the inhibition of canonical Wnt signaling. 
In addition to fluoxetine, various other types of SSRIs are frequently prescribed to reproductive-
age women. Epidemiologic studies that compiled data for all SSRIs together as a single class indicate the 
absence of a significant association between maternal SSRI intake and the occurrence of birth defects 
(Ornoy and Koren, 2017). However, fluoxetine may cause birth defects through mechanisms unrelated to 
its SSRI action, as suggested in the present study. For this reason, it is crucial to investigate the 
developmental toxicity of individual medications with consideration for unexpected off-target effects. 
Currently, animal-based tests are the gold standard to assess the developmental toxicity of chemical 
compounds. However, animal experimentation is costly, labor-intensive, and it poses ethical issues 
concerning animal welfare, especially given the large number of compounds that need to be tested. In 
vitro assays, such as the P19C5 EB morphogenesis-based tests, may be effectively used to gain valuable 
information on dose-response relationships and molecular mechanisms for a number of compounds in a 
practical and ethical manner. Our ongoing investigation using P19C5 EBs suggests that a few other 
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commonly prescribed antidepressants, notably paroxetine and sertraline, also have adverse effects on 
developmental processes. Tests like this are important because, with a better understanding of the 
properties of individual medications, physicians can choose the most appropriate options to treat 
depressed women while minimizing the risk of causing unnecessary birth defects in human babies. 
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Figure 4.1. The experimental scheme to assess the morphogenetic and molecular impact of chemical 
exposures using the P19C5 embryoid body morphogenesis system. 
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Figure 4.2. Fluoxetine impairs morphogenesis of P19C5 embryoid bodies. (A) Representative images of 
embryoid bodies (EBs) on Day 4 that have been treated with fluoxetine at the indicated concentrations. 
All images show a set of EBs that were generated from the same cell suspension. (B) Morphometric 
parameters of Day 4 EBs treated with fluoxetine. Graphs show averages of relative area (open columns) 
and relative EDI (shaded columns) with error bars representing the 95% confidence intervals. Asterisks 
indicate adverse impacts, which are defined as a reduction in average relative area by > 20% and/or a 
change in average relative EDI by > 40%, compared to the control (0 µM). All adverse impacts are 
statistically significant (P < 0.01; two-sample t-test). (C) Morphometric parameters of Day 4 EBs treated 
with fluoxetine’s R- or S- enantiomers or primary metabolite, norfluoxetine, presented in the same format 
as described for (B). No area or EDI values are available when EBs are dead (noted as “D”). (D) 
Representative images of control and compound-treated Day 4 EBs. Scale bars in (A, D) = 500 µm. 
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Figure 4.3. The morphogenetic effects of fluoxetine are not due to inhibition of the serotonin transporter. 
(A) RT-PCR products of the Slc6a2 (norepinephrine transporter) and Slc6a4 (serotonin transporter) 
mRNA, amplified from the embryoid body (EB; a mixture of Days 0, 1, 2, 3, and 4) and the mouse whole 
embryo (WE; embryonic stage E10.5) cDNAs. M: 100 bp ladder molecular marker. (B) Quantitative RT-
PCR analysis of Slc6a2 and Slc6a4 expressions in EBs, relative to the level in WE. Graphs show 
averages of relative expression levels, and error bars show standard deviation. (C) Representative 
images of Day 4 EBs treated with citalopram or venlafaxine. (D) Morphometric parameters of Day 4 EBs 
treated with citalopram or venlafaxine. (E) Representative images of Day 4 EBs that were treated with 
serotonin (5-HT). Morphometric parameters of Day 4 EBs treated with 5-HT. Graphs in (D, F) show 
averages of relative area and relative EDI with error bars of 95% confidence intervals. Scale bars in (C, E) 
= 500 µm. 
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Figure 4.4. Fluoxetine alters the expression patterns of various developmental regulator genes. (A) 
Temporal expression profiles of developmental regulator genes during EB development, determined by 
quantitative RT-PCR analysis. EBs were treated with fluoxetine (2 or 6 µM) or DMSO (control). Horizontal 
axes represent days of culture, and vertical axes represent relative expression levels in arbitrary units. 
Graphs show average relative expression levels, and error bars represent standard deviation. (B) 
Comparisons of expression profiles for Pou5f1, Nanog, and Brachyury on Days 1 and 2 between EBs 
treated with fluoxetine and EBs treated with pharmacological inhibitors of the major developmental 
signals. The disruption profiles for the WNT, NODAL, FGF, BMP, and retinoic acid (RA) signaling 
inhibitors are based on the previous study (Li and Marikawa, 2015). NS: No significant change.  
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Figure 4.5. Fluoxetine inhibits canonical Wnt signaling in P19C5 cells. (A) A schematic diagram of the 
canonical Wnt signaling pathway, highlighting the key regulatory components and pharmacological 
inhibitors (XAV939 and CHIR99021). (B, C, D) Relative luciferase activity of TOPFLASH and FOPFLASH 
(B), pG5-Luc driven by L1CBD-G4DBD and G4DBD (C), and ARE-Luc (D), in P19C5 cells in monolayer 
culture, treated with the indicated compounds for 24 hours. (E, F) Impact of fluoxetine R- or S- 
enantiomers (E), citalopram, venlafaxine, and 5-HT (F) on the relative luciferase activity of TOPFLASH in 
monolayer culture. All graphs show averages of relative luciferase activities with error bars of standard 
deviation. 
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Figure 4.6. Activation of canonical Wnt signaling partially alleviates the adverse effects of fluoxetine. (A) 
Relative luciferase activity of TOPFLASH in monolayer P19C5 cells treated with fluoxetine and 
CHIR99021 at various concentrations for 24 hours. (B) Representative images (top) and morphometric 
parameters (bottom) of Day 4 EBs treated with CHIR99021. Graphs show the averages of relative area 
and relative EDI and error bars represent the 95% confidence intervals. (C) Representative images of 
Day 4 EBs treated with fluoxetine and CHIR99021. (D) Morphometric parameters of Day 4 EBs treated 
with fluoxetine and CHIR99021, presented in the same format as described for (B). Asterisks in (A, D) 
indicate statistically significant differences between the two groups indicated (P < 0.01; two-sample t-test). 
Scale bars in (B,C) = 500 µm. 
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Figure 4.7. Trifluoromethylphenyl moiety of fluoxetine is essential in causing the adverse effects of 
fluoxetine. (A) Chemical structures of fluoxetine, norfluoxetine, nisoxetine, and XAV939. 
Trifluoromethylphenyl groups are highlighted in yellow. (B) Structure of the trifluoromethylphenyl group, in 
which a trifluoromethyl substituent is on the aromatic ring in the para position relative to R. (C) 
Representative images (top) and morphometric parameters (bottom) of Day 4 EB treated with nisoxetine. 
Graphs show averages of relative area and relative EDI with error bars showing 95% confidence 
intervals. Scale bar = 500 µm. (D) Relative luciferase activity of TOPFLASH in P19C5 cells treated with 
nisoxetine for 24 hours in monolayer culture. Graphs show average ± standard deviation of relative 
luciferase activity. 
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Figure 4.8. Fluoxetine diminishes cell proliferation independently of its inhibitory effects on Wnt signaling 
or SERT activity. (A) Impact of fluoxetine, R-fluoxetine, S-fluoxetine, norfluoxetine, and nisoxetine on the 
number of viable cells in monolayer culture after 4 days of treatment, assessed by the CellTiter-Glo 
Luminescent Assay. (B) Impact of XAV939 on the number of viable cells (left; 4 day treatment) and on the 
TOPFLASH activity (right; 24 hour treatment) of P19C5 cells in monolayer culture. (C) Impact of 
citalopram and venlafaxine (left), and 5-HT (right), on the number of viable cells in monolayer culture after 
4 days of treatment. All graphs show average and standard deviation of relative light unit or luciferase 
activity. 
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Figure 4.9. A proposed mechanism of action by which fluoxetine adversely affects morphogenesis. 
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Table 4.1. Genes examined in the fluoxetine study. 
 
Gene 
name 
Characteristics *1 Expression in 
EBs *2 
Primer sequences (5’  3’) 
Actb Cytoplasmic actin; Constitutively expressed 
house keeping gene; Used as a loading control 
to normalize the expression levels of other genes  
Constitutive F: GAGAGGGAAATCGTGCGTGACATC 
R: CAGCTCAGTAACAGTCCGCCTAGA 
Brachyury T-box transcription factor; Associated with the 
initiation of gastrulation; Expressed in the early 
primitive streak 
Day 1 peak F: CCTCGGATTCACATCGTGAGAGTT 
R: AGTAGGTGGGCGGGCGTTATGACT 
Cdx1 Homeodomain transcription factor; Expressed in 
the early primitive streak; Regulator of cranial-
caudal axial patterning 
Day 1 peak F: TCAGGACTGGACATGAGGTAGAGG 
R: TGGGAAGGTGGGCATGAGCAGGTA 
Hes7 BHLH transcription factor; Expressed in 
presomitic mesoderm; Transcriptional target of 
Notch signaling 
Day 2 peak F: CATACCCTTCTCCCACCTTTAGGC 
R: AGTGACGAGAAAGCGATTCAAAGG 
Hoxc6 Homeodomain transcription factor; Regulator of 
cranial-caudal axial patterning; Expressed in the 
neural tube 
Up-regulation 
toward Day 4 
F: TTCGCCACAGGAGAATGTCGTGTT 
R: CGAGTTAGGTAGCGGTTGAAGTGA 
Meox1 Homeodomain transcription factor; Regulator of 
somite segmentation; Expressed in somitic 
mesoderm 
Day 3 peak F: AAAAATCAGACTTCCCAGCGACAG 
R: TTCACACGTTTCCACTTCATCCTC 
Mixl1 Homeodomain transcription factor; Associated 
with the initiation of gastrulation; Expressed in 
the early primitive streak 
Day 1 peak F: CGACAGACCATGTACCCAGACATC 
R: TGAGGCTTCAAACACCTAGCTTCA 
Nanog Homeodomain transcription factor; Regulator of 
pluripotency maintenance; Expressed in the 
epiblast 
Down-
regulation after 
Day 0 
F: GCTTTGGAGACAGTGAGGTGCATA 
R: GCTACCCTCAAACTCCTGGTCCTT 
Nodal Ligand for Nodal signaling; Transcriptional target 
of Nodal signaling 
Down-
regulation after 
Day 0 or 1 
F: GTACATGTTGAGCCTCTACCGAGA 
R: TCTACAGACAGCTGTCCCTCCTGG 
Otx2 Homeodomain transcription factor; Expressed in 
the neural tube 
Down-
regulation after 
Day 0 or 1 
F: GAAACAGCGAAGGGAGAGGACGAC 
R: CCCAAAGTAGGAAGTTGAGCCAGC 
Pax3 Paired-box transcription factor; Expressed in the 
neural tube 
Up-regulation 
toward Day 4 
F: GCTTCTCAGCGTGCAATACTGTGT 
R: TTTCTGTTCTAGCCCTGCCTTTTG 
Pou5f1 POU-domain transcription factor; Regulator of 
pluripotency maintenance; Expressed in the 
epiblast 
Down-
regulation after 
Day 0 
F: AGGCAGGAGCACGAGTGGAAAGCA 
R: GGAGGGCTTCGGGCACTTCAGAAA 
Sox2 SRY-box transcription factor; Regulator of 
pluripotency maintenance; Expressed in the 
epiblast and neural tube 
Down-
regulation at 
Day 2 
F: CACATGAAGGAGCACCCGGATTAT 
R: CTGGAGTGGGAGGAAGAGGTAACC 
Sp5 Zinc finger transcription factor; Transcriptional 
target of canonical Wnt signaling; Expressed in 
the early primitive streak 
Day 1 peak F: CAGGACAGGAAACTGGGTCGTAGT 
R: GGCCTAGCAAAAACTTAGGCCTTG 
Spry2 Antagonist of RTK signaling; Transcriptional 
target of FGF signaling 
Up-regulation 
after Day 0 
F: TTGCATAAGCTAAAGCAGCCAACA 
R: TTTGTGACTGTGCCATGAAGCATA 
Tbx6 T-box transcription factor; Regulator of paraxial 
mesoderm specification; Expressed in the caudal 
end 
Day 2 peak F: GGCCTCTCTTCCACCCTTTAGTTC 
R: CACTAGTAACAAGGCCCCCAGGAG 
Wnt3a Ligand of the Wnt signaling; Regulator of paraxial 
mesoderm specification; Expressed in the caudal 
end 
Day 2 peak F: GCCACAAGAGCTTCCTGATTGGTA 
R: CCAGGCAGAAGACAGTCAGTCACC 
 
*1. Functional and structural properties of the encoded proteins and the expression patterns in normal 
mouse embryos around the time of gastrulation;  
*2. Temporal expression profiles in unmanipulated (control) P19C5 EBs based on the previous studies 
(Lau and Marikawa, 2014; Li and Marikawa, 2015, 2016) and the present study. 
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Table 4.2. Compounds used in the fluoxetine study. 
 
Compound name 
 
 
CASRN 
 
Vendor (catalog number) 
 
Stock concentration 
(solvent) 
 
Fluoxetine hydrochloride 56296-78-7 Sigma-Aldrich (F132) 
 
50 mM (DMSO) 
R-(−)-Fluoxetine hydrochloride 114247-09-5 Sigma-Aldrich (F1678) 
 
20 mM (DMSO) 
S-(+)-Fluoxetine hydrochloride 114247-06-2 Sigma-Aldrich (F1553) 
 
20 mM (DMSO) 
Norfluoxetine hydrochloride 
 
57226-68-3 Sigma-Aldrich (F133) 10 mM (DMSO) 
Citalopram hydrobromide 
 
59729-32-7 Sigma-Aldrich (C7861) 50 mM (DMSO) 
Venlafaxine hydrochloride 99300-78-4 Sigma-Aldrich (V7264) 
 
50 mM (H2O) 
5-Hydroxytryptamine 
hydrochloride 
153-98-0 Sigma-Aldrich (H9523) 
 
50 mM (DMSO) 
XAV939 284028-89-3 Sigma-Aldrich (X3004) 
 
10 mM (DMSO) 
SB431542 49843-98-3 StemCell Technologies 
(72232) 
10 mM (DMSO) 
CHIR99021 252917-06-9 Stemgent (04-0004) 10 mM (DMSO) 
 
CASRN, Chemical Abstracts Service Registry Number; DMSO, dimethyl sulfoxide;  
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CHAPTER 5. CONCLUSION 
5.1 - The future of developmental toxicology research is in vitro 
The flaws of the current animal-based developmental toxicity screens necessitate that in vivo 
testing be augmented or supplanted by in vitro systems, which are fast, cheap and robust to a variety of 
experimental techniques. The cost of in vivo testing alone is a significant factor making in vitro methods 
desirable, because the reliance on animal-based testing makes drug development prohibitively expensive 
for all but the largest pharmaceutical companies, resulting in a regulatory bottleneck that prevents 
potentially life-saving therapies from reaching patients and emphasizing the profitability of 
pharmaceuticals over medical need. To address a small part of this issue, the FDA relaxed the 
requirement for regulatory testing for “orphan drugs,” medications that are developed to treat, diagnose or 
prevent rare illnesses. Globally, 6-8% of the population is affected by one of approximately 7,000 rare 
diseases. The prohibitive cost of drug development means that very few treatments for these diseases 
are brought to market (Gammie et al., 2015; Blankart et al., 2011; Franco, 2013). Although reducing the 
regulatory requirements for this small group of drugs may help a few beneficial therapies reach patient 
populations, the vast majority of potential pharmaceuticals face a gauntlet of regulatory testing. To reduce 
the cost of drug development and promote the search for new beneficial medications, we should 
emphasize increasing the ease and efficiency of regulatory test methods using the myriad in vitro 
technologies that have been developed since 1966 rather than depending solely on outdated animal-
based methods. Additionally, the relevance of in vivo DART testing results to human pregnancies is not 
always clear. As seen with the thalidomide tragedy, the “apical endpoints” that result from in vivo DART 
testing, such as fetal death or malformation, are not well-suited for comparisons between species and 
sometimes are inconsistent even within strains of the same species (Tonk et al., 2015). However, since 
the mechanisms that regulate embryogenesis—particularly within mammals—are highly conserved, “it is 
anticipated that mechanistic information on the interference of chemicals with embryogenesis on the 
molecular level would provide a more informative background for hazard and risk assessment for 
man…such approaches not only allow a more detailed insight into mechanisms of dysmorphogenesis in 
animals, but also facilitate direct comparison with the human situation” (Tonk et al., 2015). Although it is 
difficult to elucidate teratogenic mechanisms in animal-based models, in vitro tests are well suited for this 
type of hypothesis-based developmental toxicity research.  
In vitro tests are advantageous in many ways. Relative to in vivo testing, in vitro test methods 
make it easier to standardize experimental conditions and allow more objective quantification of results. 
For DART testing, pregnant animals are usually dosed by body weight, which, combined with individual 
differences in maternal metabolism and discrepancies in experimenter techniques, leads to large 
variability in the actual fetal exposure to the treatment chemical. In vitro systems allow better control of 
experimental variables and more accurate treatment doses. Similarly, the outcomes of DART studies are 
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obtained by semi-quantitative scoring of fetal malformations, which requires extensive experimenter 
training and potential for human error. In vitro systems allow objective quantification of experimental 
endpoints and reduce inter-laboratory variability. Additionally, while in vivo methods are cumbersome and 
low-throughput, in vitro models allow high-throughput screening of hundreds or thousands of chemicals, a 
scalability that is increasingly needed for regulatory testing. Finally, in vitro systems are advantageous 
because they provide a platform for many different types of experimentation that are difficult or impossible 
using animal models. Using multiple stem cells lines, it is easy to assess whether a chemical is generally 
toxic or whether it causes toxicity in a specific type of cell. Additionally, embryonic stem cells can be 
directed to differentiate into specific tissue types or recreate certain processes of embryonic development 
in vitro. This allows a better understanding of teratogenic susceptibility to a given chemical and makes it 
easier to extrapolate to humans.  
Perhaps the most useful aspect of in vitro developmental toxicity testing, particularly in 
mechanistic evaluations, is the use of gene expression analyses. In contrast to the high volume of 
chemicals tested using high-throughput methods, gene expression analyses, a.k.a., toxicogenomics, 
enable high-content screening of potentially teratogenic chemicals. This is a major component of the 
SEURAT (‘Safety Evaluation Ultimately Replacing Animal Testing’) initiative and was discussed 
extensively in the publication that summarized results of the SEURAT first phase: “Methods such as 
toxicogenomics are attractive because virtually all toxic responses are preceded by changes in gene 
expression, and the pattern of gene expression can be diagnostic of mode of action and ‘critical biological 
targets’. Furthermore, because gene expression analysis usually covers the entire genome, the 
methodology is able to detect off-target effects provided that the offending target or pathway is expressed 
in the model system(s) being tested. There is already a reasonable amount of research to show that 
toxicogenomic responses from in vitro systems are rich enough to recapitulate in vivo responses, but 
more needs to be done to fully define the potential and limitations of in vitro systems as the platforms for 
toxicogenomics” (Daston et al., 2015). High-content assays allow investigation of biological responses to 
developmental toxicants at cellular and molecular levels and are increasingly valuable as a method of 
understanding teratogenic mode of actions (Knudsen et al., 2011). Between the breadth of analysis 
offered by high-throughput methods and the depth of mechanistic understanding achieved with high-
content toxicogenomic assays, in vitro models are changing the field of developmental toxicology for the 
better.  
The dose of chemical used in developmental toxicity testing remains an important consideration 
that has been difficult to address with in vivo DART methods. Teratogens are not always teratogenic. The 
developmental toxicity of a chemical varies based on the magnitude and timing of embryonic exposure. 
Ideally, developmental toxicity testing would identify the exact concentrations at which a chemical 
exposure goes from having no effect (NOAEL) to causing structural malformations in susceptible 
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embryos. However, this is difficult to do in vivo due to the effects of maternal metabolism, chemical-
specific pharmacokinetics, and a relatively limited window of teratogenic susceptibility. Historically, 
pregnant animals are treated relatively infrequently with high-dosages of the test chemical, and only a few 
different dosages are tested, which is problematic for several reasons. First, human exposures usually 
occur at chronic low-level doses, and it is likely that some teratogenic effects will be the result of the 
cumulative damage to target tissues or organs over time, which is not reflected in the dosing profile of in 
vivo protocols even with the same cumulative daily exposure (Scialli et al., 2018). Additionally, different 
exposure levels of a teratogenic chemical are likely to activate different adverse outcome pathways 
(Ankley et al., 2010). This effect was seen in the case of fluoxetine, which affects serotonin reuptake at 
therapeutic concentrations, inhibits canonical Wnt signaling at slightly higher concentrations and 
adversely affects cellular proliferation and viability via an unknown mechanism(s) at even higher 
concentrations. Third, high dosages like those used in animal models may cause fetal death and obscure 
the presence of malformations occurring at lower doses. “[D]ose metric provides the most meaningful 
basis for interpreting observed effects” of DART testing in animal models to a prediction of the effects in 
human pregnancies (Ankley et al., 2010). Without establishing dose-response curves for teratogenic 
effects, it is risky to attempt to extrapolate results to an estimate of human risk. In vitro tests are well-
suited to aid in the creation of dose-response curves because it is easy to alter doses to more accurately 
match human pharmacokinetic data and gene expression assays are often able to give an indication of 
dose-response before effects are seen at the organ or organism level. Therefore, discussion of dose is a 
perfect example of how in vitro testing methods can supplement, inform and enhance the power of in vivo 
testing.  
Despite many advantages, there are limitations to in vitro screening that must be addressed. The 
robustness, flexibility and efficiency of in vitro tests largely come from their inherent simplicity. Rather than 
trying to understand drug effects on multiple organ systems, in vitro screens assess effects on a single 
cell type. As a result, it is unlikely that any single in vitro assay will be able to fully represent the broad 
spectrum of teratogenic susceptibility during development. To address this, coordinated panels of in vitro 
models, each representing different developmental stages or cell types, will likely be used together to 
screen for teratogenic chemicals. Even so, there is a limited ability of in vitro cells to represent the 
collective responses of tissues within a complex organism, which maintains homeostasis through several 
compensatory mechanisms. The best example of this is the effect of maternal metabolism on the actual 
embryonic exposure to developmental toxicants. Although it may be possible to simulate maternal 
metabolism in vitro, that and other aspects of biologic adaptability remain a hurdle for in vitro screens 
(Luijten et al., 2008). Additionally, a model is only valuable to the extent that it can simulate the process or 
system that we wish to predict. To accurately interpret the results of in vitro screens, we must understand 
what embryologic processes are represented and ensure that those processes are a valid reflection of 
human biology or development. Many in vitro models attempt to mimic a complex developmental process 
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in the absence of the three-dimensional structural complexity, patterning, spatial dynamics and cellular 
interactions that are ubiquitous in organismal development (Tonk et al., 2015). This issue was also 
discussed by Scialli et al. as well, as they wrote, “When modeling developmental processes and the 
toxicity that disrupts them, we need to rebuild this complexity” (Scialli et al., 2018). The balance between 
quantifiable simplicity and realistic complexity will likely be addressed through the coordination of a 
variety of in vitro models and advancements in the way developmental toxicology data is accumulated 
and processed (De Abrew et al., 2016; Ankley et al., 2010; Knudsen et al., 2011). If we remember the 
limitations of in vitro models and interpret results accordingly, these alternative developmental toxicity 
assays are a powerful tool in the study of teratology and embryonic development.  
5.2 - The P19C5 morphogenesis model adds complexity to in vitro 
developmental toxicity screens 
P19C5 model recreates some of the structural complexity and cellular heterogeneity that many in 
vitro models lack. After the initial induction of differentiation, P19C5 EBs do not require any additional 
experimental manipulations to undergo in vitro processes similar to embryonic gastrulation and 
morphogenesis. Since EBs demonstrate a substantial ability to self-organize and establish body axes and 
patterning in a consistent temporal manner, it is likely that they are following the early progression of 
developmental steps that create embryonic complexity in vivo. The process of morphogenesis represents 
the successful function of many critical processes, so the consistent Day 4 elongation of EBs further 
supports that prerequisite developmental processes are also represented in the P19C5 embryoid body 
model. A biologically active chemical can exert effects in three general manners: 1) acting against a 
single specific target or pathway, 2) non-selectively disrupting many pathways or targets (e.g., chemicals 
that have general toxicity), and 3) affecting multiple, unrelated biologic pathways partially selective 
manner. In making recommendations for the field of predictive toxicology, Daston et al. (2015) assert that 
this third type of chemical is the most difficult to using in vitro systems and that, “[s]uch chemicals with 
pleiotropic behavior will probably require more sophisticated systems biology approaches to predict which 
types of toxicity might be anticipated, and at what concentrations” (Daston et al., 2015). Because P19C5 
EBs demonstrate a higher level of complexity than most in vitro models, they may be better suited to 
identify the teratogenic chemicals that have pleiotropic effects and can disrupt several developmental 
pathways. Finally, the P19C5 model is useful because it can be used for high-content genomic assays 
and may be amenable to modifications allowing high-throughput screening. Because the P19C5 EBs are 
simple to create and are evaluated using simple morphologic parameters that can be assessed with 
largely automated image analysis software, it is theoretically possible to automate many parts of the 
P19C5 model in a way that would allow high-throughput screening. If P19C5 EBs are to be used in 
regulatory testing, we also must consider the limitations of the model. P19C5 cells are a murine stem cell 
line, and like in vivo rodent models, the P19C5 cells do not respond to primate-specific teratogens like 
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thalidomide. In the future, we would like to create a similar morphogenesis-based model using human cell 
lines, which would respond to these species-specific developmental toxicants. Additionally, P19C5 EBs 
develop and elongate without detectable Shh signaling activity, which is crucial for normal development of 
anterior structures. This may be because P19C5 EBs appear to recreate only the caudal portion of 
embryonic gastrulation and elongation morphogenesis. If so, it is appealing to hypothesize that the high 
activity of caudal signaling pathways such as RA, Fgf and Wnt may suppress Shh activity. Nonetheless, it 
is important to consider the advantages as well as the limitations of the P19C5 model when it is applied to 
developmental toxicity research.  
5.3 - Future directions and concluding remarks 
Within the past decade, the focus in developmental toxicology has shifted away from animal-
based testing methods towards in vitro methods. Animal-based toxicity screens are an unwieldy, low-
throughput approach that cannot reasonably meet the need to comprehensively screen high numbers of 
chemicals for potential developmental toxicity. In 2007, the National Research Council released the 
report, “Toxicity Testing in the 21st Century,” (TT21C) which emphasized the need for a paradigm shift in 
regulatory toxicology towards an approach based on in vitro methods capable of high-throughput 
screening of chemicals rather continuing the traditional reliance on resource-intensive in vivo models 
(Committee on Toxicity Testing and Assessment of Environmental Agents, 2007). The TT12C report 
described the value of assessing teratogenic mechanisms and discussed the concept of “toxicity 
pathways” as a framework for the study of teratogens. The TT12C report was followed by the 
Organization for Economic Co-operation and Development (OECD) report in 2012 that promoted adverse 
outcome pathways (AOPs) as a more informative and relevant structure for future DART research and 
screening. Although the terminology varies slightly, the NRC toxicity pathways and the OECD adverse 
outcome pathways, represent similar functional paradigms that emphasize the importance of identifying 
the molecular initiation event (MIE) for any given teratogen. Ankley et al. (2010) defined the AOP as, “a 
conceptual construct that portrays existing knowledge concerning the linkage between a direct molecular 
initiating event and an adverse outcome at a biological level of organization relevant to risk 
assessment…[and] can focus toxicity testing in terms of species and endpoint selection, enhance across-
chemical extrapolation, and … facilitate use of molecular or biochemical endpoints (sometimes referred to 
as biomarkers) for forecasting chemical impacts on individuals and populations.” (Ankley et al., 2010). 
The AOP provides a structure for mechanistic information from many types of toxicologic models to be 
integrated into a single cohesive description of teratogenic mechanism.  
Compared to in vivo DART testing, the AOP method of DART assessment allows more inclusive 
incorporation of existing knowledge on teratogenic mechanisms, a better identification of endpoints 
relevant to assessing human risk, and more efficient delegation of limited resources for DART testing to 
the areas where additional information on teratogenic mode of action is vital to risk assessment (Ankley et 
91 
 
al., 2010). If testing is done at the mechanistic (or “mode of action” level), then it may be possible to 
identify “critical biological targets” (Daston et al., 2015) that will enable the identification of “a small 
number of key events at a molecular or cellular level that predict an adverse outcome for which testing 
could be preformed in vitro or in silico or, rarely, using limited in vivo models” (Scialli et al., 2018). The 
future of developmental toxicology research will emphasize the importance of the third of Wilson’s 
principles: “Developmental toxins act in specific ways (mechanisms) on developing cells and tissues to 
initiate sequences of abnormal developmental events (pathogenesis)” (Faqi et al., 2012). This represents 
a hypothesis-based approach to teratology research that seeks to answer key questions rather than 
blindly screening chemicals using outdated methods. “A key component in the development of 
hypothesis-driven testing is the understanding that there are a finite number of modes of action involved 
in developmental toxicity. We do not yet know all possible modes of action or the number of pathways 
that could be involved, but we believe that these pathways are knowable” (Scialli et al., 2018). The AOP 
framework allows the integration of information from several in vitro models to create a comprehensive 
picture of potential developmental toxicity for a given chemical that can be more easily extrapolated to a 
risk assessment in human pregnancies. The P19C5 model and other in vitro systems are a promising 
addition to the field of developmental toxicology research and may one day be a fundamental part of 
regulatory DART testing for pharmaceutical chemicals.  
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APPENDIX A: MACRO SCRIPT FOR IMAGEJ MORPHOMETRIC ANALYSIS 
OF EBS 
I wrote the following macro code to semi-automate the morphometric analysis of P19C5 EBs. 
This ImageJ macro (written in the ImageJ language, “.ijm,”) enabled EB images to be analyzed in 
approximately one tenth of the the amount of time that it took to outline EBs by hand, using the polygon 
selection tool in ImageJ. In order for the P19C5 system to accommodate high-throughput analyses, it 
must be amenable to automation and modifications that increase efficiency. Since a major drawback of 
both in vivo testing and the ESTc is the necessity for skilled, semi-quantitative scoring of apical endpoints, 
this macro demonstrates that the P19C5 system may be an advantageous innovation for high-throughput 
screening in DART testing.  
Yellow highlighted regions within the following code indicate command sequences that are 
illustrated with pictures in Appendix B. The bold, red letters corresponding to the highlighted phrases 
indicate which picture matches the text and are not part of the macro code. The macro code is as follows: 
  roiManager("reset"); 
(A)  path = File.openDialog("Select file"); 
  open(path); 
   
(B) Dialog.create("EB Image Analysis Parameters"); 
   Dialog.addNumber("Analyze_Partcles_(Min):", 10000);  
   Dialog.addNumber("Analyze_Partcles_(Max):", 10000000); 
   Dialog.addNumber("Interpolation Interval:", 1); 
   Dialog.show(); 
    
   APmin = Dialog.getNumber(); 
   APmax = Dialog.getNumber();; 
   Interval = Dialog.getNumber();;; 
   
  name=File.nameWithoutExtension; 
  parent=File.getParent(path); 
(C) run("Set Scale...", "distance=0.3940 known=1 pixel=1 unit=uM global"); 
   
  run("Duplicate...", name+"-1"); 
(D) run("Invert"); 
(E) imageCalculator("Min create", name+"-1.tif", name+".tif"); 
  selectWindow("Result of "+name+"-1.tif"); 
   
(F) run("Find Edges"); 
  run("8-bit"); 
(G) setMinAndMax(0, 125); 
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  call("ij.ImagePlus.setDefault16bitRange", 8); 
  run("Apply LUT"); 
  setMinAndMax(40, 125); 
  call("ij.ImagePlus.setDefault16bitRange", 8); 
  run("Apply LUT"); 
   
(H) //setTool("brush"); 
  setLineWidth(3); 
  setForegroundColor(0,0,0); 
  setBackgroundColor(255,255,255); 
   
(I) waitForUser("Pause","Separate EBs with Paintbrush tool (Color = Black,  
  Brush Width = 3 pixels). Click OK when done."); 
   
   
(J) run("Make Binary"); 
   
  for(i=0;i<3;i++){ 
(K)  run("Close-"); 
(L)  run("Fill Holes"); 
  } 
   
  waitForUser("Pause","Are all EBs complete and/or separated? Click OK if  
  yes."); 
   
(M) run("Erode"); 
   
 run("Analyze Particles...", "size=&APmin-&APmax clear add"); 
   
  roiManager("Show All with labels"); 
  for(i=0; i<roiManager("count"); i++){ 
   roiManager("select", i); 
  run("Interpolate", "interval=&Interval"); 
(N)  run("Fit Spline"); 
   roiManager("Update"); 
  } 
   
(O) run("Set Measurements...", "area mean standard modal min centroid center  
  perimeter bounding fit shape feret's integrated median skewness kurtosis  
  area_fraction display add redirect=None decimal=3"); 
  roiManager("Deselect"); 
  selectWindow(name+".tif"); 
  roiManager("Show All with labels"); 
(P) roiManager("Measure"); 
94 
 
  selectWindow(name+".tif"); 
  save(path); 
   
  output=getDirectory("Choose Folder for Results"); 
  selectWindow("Results"); 
  saveAs("Results", output+name+"_results.csv"); 
   
  selectWindow(name+"-1.tif"); 
  close(); 
  selectWindow("Result of "+name+"-1.tif"); 
  close(); 
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APPENDIX B: EXAMPLE IMAGES CORRESPONDING TO APPENDIX A 
MACRO SCRIPT FOR IMAGEJ MORPHOMETRIC ANALYSIS OF EBS 
Images to accompany EB image analysis macro script are demonstrative of the general concepts 
and .ijm commands only. Different ImageJ versions may look slightly different. Some variables of the 
macro sccript (i.e., particle size, min/max threshold, etc.) may need to be adjusted if using this macro for 
images captured through any methods other than those described in the materials and methods portions 
of the preceding text. 
(A) Open file (B) Set EB particle size (C) Set scale 
 
 
 
(D) Duplicate and invert (E) Min create (F) Find edges 
  
 
(G) Set min/max threshold (H) Select brush tool (I) Separate EBs with 
brush tool* 
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(J) Make binary (K) Close (L) Fill holes 
   
(M) Erode (N) Interpolate/fit spline (O) Set measurements 
  
 
(P) Measure   
 
* Note: Brush lines in (I) were 
illustrated in red. During actual 
image analysis brush lines 
would be black. 
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